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Abstract
Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by weakness and muscle
atrophy. Due to the chronic nature of SMA, it is important to understand the health-related
quality of life among children affected by this disease. Participants were recruited from the
Canadian Neuromuscular Disease Registry, where 45 families completed the Pediatric
Quality of Life Inventory questionnaires. Results from the child self-report and parent proxy
questionnaires were compared to those of healthy children and children with Duchenne
Muscular Dystrophy. Agreement between parents and children was assessed using paired ttests and intraclass correlation coefficients. Additionally, multivariable linear regressions
were used to determine child and family characteristics associated with health-related quality
of life outcomes. Higher levels of perceived fatigue were consistently associated with lower
health-related quality of life outcomes. Based on the results, interventions to reduce fatigue
could lead to improvement of health-related quality of life for children with Spinal Muscular
Atrophy.
Keywords: Spinal muscular atrophy, cross-sectional study, health-related quality of life,
fatigue, parent proxy, quality of life
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Summary for Lay Audience
Spinal muscular atrophy is one of the most common fatal genetic childhood diseases. This
motor nerve disorder causes weakening of the muscles. Due to the serious and long-term
nature of spinal muscular atrophy, it is important for healthcare workers and researchers to
try to understand and improve the health-related quality of life in children with this disease.
In this study, both children with spinal muscular atrophy and their parents filled out
questionnaires asking about the child’s health-related quality of life. We looked at whether
scores from children with spinal muscular atrophy were different than scores from healthy
children and children with another neuromuscular condition. We also assessed whether
children and their parents had similar scores, and lastly, we looked at any social or clinical
factors that may be related to a child’s health-related quality of life.
The health-related quality of life scores of children with SMA were worse compared to those
of healthy children in all domains, and worse in the physical domains compared children
with another neuromuscular condition. The agreement between children and parent scores
ranged from good to poor, with parents reporting lower scores in most topics compared to
their children. Lastly, fatigue was the factor most associated to worse HRQL scores.
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Chapter 1
1.0 Introduction and Research Objectives
1.1 Background
This chapter consists of a brief overview of spinal muscular atrophy (SMA), the
constructs of quality of life (QoL) and health-related quality of life (HRQL), the
measures used to assess HRQL in children and their parents/caregivers, and lastly the
objectives and hypotheses of this study.
SMA is an autosomal recessive neurodegenerative disease, characterized by atrophy of
the muscles and generalized weakness.(1) With an incidence of 1 in 6,000 to 1 in 10,000
live births per year, it is the most common cause of lower motor neuron disease and one
of the most common fatal childhood genetic diseases.(2) The prevalence of the carrier
state is approximately 1 in 54.(3, 4) Due to the serious and chronic nature of this
neuromuscular (NM) disease, it is important to understand and improve HRQL in this
population. Although there is no cure for SMA, new therapies such as gene therapy, have
dramatically changed the clinical picture and ongoing medical advances have resulted in
increased interest in SMA research, especially understanding function and outcomes from
a patient perspective.
The goal of this study is to assess the HRQL of children with SMA from both the
children’s and parents’ perspective. It is important to understand both perspectives,
because there are circumstances in the context of SMA where the child is too young, or
too ill to report on their own HRQL. It is also commonly the parents’ perceptions of their
child’s HRQL that are used to inform their child’s treatment decisions. Furthermore,
there is still a limited understanding of the dynamic and relationship between the parent
and child HRQL perspectives in chronic childhood diseases. In this study, we aimed to
examine both the child reported and parent/caregiver proxy HRQL scores whenever
possible and examine the extent of agreement between these two perspectives. Lastly, we
aimed to explore associations of both the child reported and parent/caregiver proxy
HRQL scores with clinical and family characteristics.
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1.2

Spinal Muscular Atrophy

Individuals with SMA have insufficient levels of the survival motor neuron
(SMN) protein due to the loss or mutation of the SMN1 gene on the chromosome 5q13.
The lack of SMN protein leads to the loss of motor neurons with the downstream effect
being muscle weakness. SMA is inherited in an autosomal recessive manner, meaning
that the affected individual has two mutated genes, often inheriting one from each parent.
If an individual only has one mutated gene, they are a carrier but are not affected by SMA
or do not exhibit any symptoms.(1, 5) Two carriers have a 25% chance of having an
affected child, and in 2% of patients with SMA, only one parent is a carrier, and a new
mutation in the offspring results in SMA. A pseudogene called SMN2, differs from
SMN1 by a single nucleotide in an intronic region adjacent to exon 7, resulting in an
mRNA splicing phenomenon that excludes exon 7, and thus produces a protein that is
unstable and not as functional. Only 10-20% of the SMN2 protein is fully functional,
resulting in a spectrum of disease severity that is inversely correlated to the number of
copies of SMN2.(3) The higher the SMN2 copy number, the milder the clinical
phenotype. Therefore, type 1 SMA patients usually have no more than two copies, and
the type 3 patients have four or more copies. (2)
The most common forms of SMA can be categorized into four different groups,
based on the highest milestone achieved.(5) Type 1 (Werdnig-Hoffmann disease or
infantile-onset SMA) is the most common type of SMA, accounting for approximately
50% of patients with SMA. Type 1 SMA is also the most severe type, with common
symptoms including hypotonia (reduced muscle tone), diminished limb movements, lack
of tendon reflexes, fasciculations, swallowing and feeding difficulties, and impaired
breathing.(1) Children with type 1 SMA typically do not live past two years of age.
Children with type 2 SMA (intermediate) usually do not present with their first symptoms
until 6-18 months of age. They can sit without support but are unable to stand or walk
unaided, and some may lose the ability to stay seated independently over time without
treatment.(1) The progression of the disease is variable depending on the treatments
received and the life expectancy is up to adolescence or early adulthood. Children with
type 3 SMA (Kugelberg-Welander disease) develop symptoms after 18 months of age
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and the symptoms can be very heterogenous. Children with type 3 SMA usually meet all
their major motor milestones, such an independent walking. Considering the symptoms
are heterogenous for type 3 SMA, some children may require wheelchair assistance,
whereas others may be able to walk independently with minimal muscular weakness.(1)
With appropriate medical care, most children with SMA type 3 have a normal lifespan.
People with type 4 SMA develop symptoms in adolescence or adulthood and are fully
ambulatory with mild motor impairment, and no reported respiratory or nutritional
problems.(1) Similar to type 3 SMA, with appropriate management, most patients with
SMA type 4 have a normal expectancy.
Genetic testing is widely available to detect deletions or mutations of the SMN1
gene. This test identifies at least 95% of SMA type 1, 2, and 3 and may also reveal if a
person is a carrier of a defective gene that could be passed on to children.(5) The absence
of the SMN1 exon 7 confirms the diagnosis, with 95% sensitivity and almost 100%
specificity.(4) However, if the typical SMN mutations are not found, additional tests can
also be performed. These additional tests include electromyography (which records the
electrical activity of the muscles during contraction and at rest), nerve conduction studies
(which measure the nerve’s ability to send an electrical signal), muscle biopsy, and
sequencing of the SMN1 gene or RNA qualifications. (4, 5)
There are currently a few therapies available for the treatment and management of
SMA. Nusinersen is the first drug approved by the Food and Drug Administration (FDA)
to treat children and adults with SMA. It is an antisense oligonucleotide drug that
modulates pre-messenger RNA splicing of the SMN2 gene, increasing the production of
functional SMN protein. The drug is administered by injection into the fluid surrounding
the spinal cord. Multiple multicenter, double blind, sham-controlled trials comparing
nusinersen to placebo (6) found that those with early or later onset SMA who received
nusinersen had significant improvement in motor function, compared to the control
group. (6-8)
In addition to drug therapy, gene therapy has also been used for SMA. This
method uses an AAV9 viral vectors to replace SMN1.(4) Onasemnogene abeparovec-xioi
(Zolgensma ™) is a gene therapy drug approved by the FDA in 2019. (9) This drug is
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generally intended for children less than two years of age who have type 1 or infantile
onset SMA. (9) The drug is administered by having a viral vector deliver a full functional
SMN gene to the targeted motor neurons.(5, 10) If successful, this drug may improve the
muscle movement and function, thus improving survival. (10) Lastly, in August 2020, the
FDA approved the first orally administered drug, risdiplam (Evrysdi), to treat patients
aged two months of age and older with SMA.(5, 11) EVRYSDI is a pre-mRNA splicing
modifier of SMN2 designed to treat SMA. The drug increases the body’s production of
the SMN protein and sustains the amount of SMN protein in the body, which helps treat
SMA.(11)
There are also other treatments aimed at managing the symptoms of SMA
including physical therapy, occupational therapy, and rehabilitation. These therapies aim
to improve posture, slow muscle weakness and atrophy. Stretching and strengthening
exercises may help reduce contractures, increase range of motion, and keeps circulation
flowing. Some individuals may also require additional therapy for speech and swallowing
difficulties, as well as require assistive devices to improve and maintain their
independence such as wheelchairs, braces, speech synthesizers etc.(5)

1.3
1.3.1

Health-Related Quality of Life
Quality of Life and Health-Related Quality of Life

QoL and HRQL are often used interchangeably in the literature, however they are actually
distinct constructs.(12) The World Health Organization (WHO) defines QoL as
“individuals’ perception of their position in life in the context of the culture and value
systems in which they live and in relation to their goals, expectations, standards, and
concerns. It is a broad ranging concept affected in a complex way by the person’s physical
health, psychological state, level of independence, social relationships, personals beliefs
and their relationship to salient features of their environment.”(13) This is in comparison
to HRQL which focuses on the impact of illness and treatments on a person’s life and does
not pertain to aspects of life that are not influenced by healthcare intervention.(14, 15)
For the purpose of this study, we focus on HRQL. Although the definitions of HRQL
vary greatly, there are two central themes found in most definitions. The first is that
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HRQL is subjective and should be assessed from the patient’s perspective, if possible.
Secondly, HRQL is multidimensional and includes a broad range of outcomes.(16)
HRQL includes patients’ assessment of their current level of functioning and their
satisfaction with it, compared to what they believe to be ideal.(17) Due to the
interchangeable use of the QoL and HRQL terms in the existing literature, the term that
most accurately describes the concept being measured will be used, regardless of whether
authors may have mislabeled HRQL as QOL.

1.4

Health-Related Quality of Life Measurements

There are many reasons why measuring HRQL is important. First, in the context of
the epidemiologic transition, health issues in the developed world have moved from
predominantly infectious and short-term diseases to more long-term chronic diseases.(18)
Since people are now living longer with chronic conditions, it is important to understand
their perspective of disease by measuring their HRQL. Thus, HRQL questions have
become an important component of public health surveillance and are generally considered
valid indicators of unmet needs and intervention outcomes.(19) HRQL can also be
foundational in the context of health economics and informing public policy for therapies.
There is also growing interest to include HRQL outcomes in clinical trials as endpoints to
evaluate changes in morbidity and medical interventions.(20, 21) Secondly, although
physiologic measures provide information to health providers, those measures often poorly
correlate with the patients’ functional capacity.(14) HRQL may also vary greatly among
people, and thus two people with the same diagnosis and physical functioning status may
have vastly different HRQL scores.(14, 22) Third, the HRQL of an individual is not
constant and may undergo different trajectories over time, which can impact the
understanding of their condition and inform their treatment.(23) Lastly, the identification
of factors contributing to HRQL that are modifiable can help both clinicians and
researchers to improve management of a disorder(24)
Based on these reasons, clinicians and policymakers recognize the importance of
measuring HRQL to have a more comprehensive understanding of the effects of chronic
conditions, as well as to inform patient management and policy decisions.(14) Regarding
the health regulatory pathways, HRQL is accepted as a key patient reported outcome (PRO)
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by both the FDA and the European Medicines Agency (EMA). The EMA requires reports
of improvement in HRQL to be supported by data collected from instruments validated for
the corresponding condition. The FDA requires PRO instruments to assess and measure
concepts of interest, and if one does not exist, the sponsor is required to develop a new
instrument or modify an existing one.(25-27)

1.4.1

Health-Related Quality of Life in Children
The assessment of HRQL in children and adolescents with chronic illnesses has

become increasingly important since children are living with these illnesses for a longer
period of time.(20) When assessing HRQL in children specifically, it is important to take
into consideration that children are embedded within multiple social contexts, such as their
family, classroom, peer groups; each of these social settings may impact their HRQL.(16)
Studies show that children can begin reporting their own HRQL between the ages
of four to six years.(28) Although children as young as four are able to provide information
on concrete aspects of their health status such as pain and medication use (16), the more
subjective domains such as emotional impact of disease are more appropriate for
assessment by older children.(16)

1.4.2

Health-Related Quality of Life and Parent/Caregiver Proxy in
Children
Similar to adults, older children are the best informants of their own HRQL.

However, some children may be too young, too ill, or cognitively impaired to assess and
report their own HRQL or they may not be able to understand the language in a
questionnaire, hence a parent or caregiver proxy is sometimes necessary.(21) A
parent/caregiver proxy is also important because it is commonly the parents’ perceptions
of their child’s HRQL that are used in their child’s healthcare decisions.
Previous research has shown a greater agreement between parents and children in
HRQL measures when assessing observable functions such as physical functioning.(14)
However, there is less agreement when measuring non-observable functions such as
social or emotional HRQL.(14, 29) Even though agreement is higher in the physical
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domain, proxy respondents still overestimate children’s dysfunction, compared to how
children rate their own functional limitations. Research also showed that agreement on
HRQL is better between parents and chronically ill children, compared to parents and
healthy children, but no differences were found across age, gender or disease groups.(29)
Overall, both the child and parent/caregiver proxy perspectives offer valuable
information, and it has been recommended that HRQL assessments be collected from
both viewpoints. (29-31)

1.5 Objectives and Hypotheses
Using a cross-sectional sample of children with SMA, the objectives of this study were:
1.

To describe HRQL from the children’s and parent/caregiver’s perspectives.
As a reference, HRQL of those with SMA were compared to published data
on HRQL in similar-aged healthy children, and children with a chronic NM
disease from the children’s and parents’ perspectives.
Hypothesis: Children with SMA will have a lower HRQL compared to
healthy children. Children with SMA will have similar HRQL compared to
children with another chronic NM.

2.

To examine the extent of agreement between the child reported and
parent/caregiver proxy-reported HRQL among older children. Only older
children (≥ 5 years) will be included in this analysis, given that children < 5
years were not asked to assess their own HRQL.
Hypothesis: Children’s self-assessments of their HRQL and the assessments
from their parent/caregiver are more similar for physical domains than for
emotional/social domains of HRQL.

3. To explore the associations of clinical and family characteristics to both the
child reported and parent/caregiver proxy assessments of HRQL.
Hypotheses:
1. Children whose families have higher social economic status have better
HRQL, as reported by both child and parent/caregiver, than children from
families with lower socio-economic status.
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2. Children who have a lower level of functioning (i.e., poorer ventilatory
status, have scoliosis and are non-ambulatory) have poorer HRQL as reported
by both child and parent/caregiver.
3. Children who are diagnosed with a more severe type of SMA have poorer
HRQL, as reported by both child and parent/caregiver, compared to children
who are diagnosed with a less severe type of SMA.
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Chapter 2
2.0 Literature Review
A systematic literature review was performed to inform the study of HRQL in
children with SMA. This chapter consists of the selection process and eligibility criteria
for the literature review, the data extraction and analysis process, the results of the
review, the discussion, and limitations of the included studies and lastly the conclusion.
There were four main objectives from the literature review:
1. To identify the HRQL measures currently used in the SMA population.
2. To assess the studies that compared HRQL in the SMA population to
healthy children and children with other conditions.
3. To assess the studies including both the parent/caregiver proxy and child
reports and how they are correlated.
4. To identify the family and clinical characteristics associated with patients’
HRQL scores as assessed by either the child and/or parent proxy.
The findings from the first and second objectives were used to evaluate the
current landscape of HRQL in the SMA population and examine whether the level of
HRQL in this population differs from levels in other populations. The findings from the
third objective were used to identify the clinical and family characteristics to include in
the multivariable regression. The results from the final objective of the review were used
to contextualize the results of this study related to the agreement between the
parent/caregiver proxy and child reported HRQL.
The literature review was conducted from inception to November 29, 2020, in
MEDLINE, EMBASE and Cochrane CENTRAL. Search terms included “spinal
muscular atrophy”, “SMA”, “Healthy related quality of life”, “HRQL”, “HRQOL”,
“Pediatric”, or “Child”. The full search strategy is located in Appendix A.

2.1 Study Selection and Eligibility Criteria
All study types including observational and clinical trials were included. Studies
were eligible for inclusion if: 1) the study population included children (<18 years)
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diagnosed with SMA (type 1, 2, 3 or 4) and/or their parent/caregiver proxy and 2) HRQL
or QOL was assessed as an outcome in children with SMA, either as reported by the child
and/or parent/caregiver proxy. Studies were excluded if they were non-English studies,
measured HRQL in children with other diseases, or only included adults with SMA.
One researcher (T.N.) screened abstracts for eligibility. If there was an abstract
and full-text publication of the same study meeting the inclusion criteria, the full-text
publication was included, and the abstract was excluded. Any questions that were raised
during the screening was resolved by a second researcher (C.C.).

2.2 Data extraction and analysis
Data were extracted into a Microsoft excel spreadsheet. The following study design
characteristics were extracted: 1) trial design and participant characteristics (author, year
of publication, country of publication, study design, age of participants and sample size);
2) the main objectives of the studies; 3) the measure/questionnaire used to assess the
HRQL of the participants; 4) the main findings from the studies; and 5) the clinical or
demographic factors correlated to HRQL scores.

2.3 Results
The search yielded 441 results and after removal of duplicate studies, 316
abstracts were screened, and 35 full text studies were selected for full-text review.
Thirteen studies were excluded after full-text review (Table 2-1), leaving 21 included
studies (Table 2-2). The main reasons for exclusion included: 1) the studies only
assessing HRQL of the parent/caregiver and not of the child, 2) abstracts of full text
studies that were already included, and 3) the study including children with different
types of NM diseases.(32-52) The PRISMA diagram is located in Appendix B.

Included Studies
The 21 included studies were published between 2011 and 2020 and conducted in
Australia, Brazil, Czech Republic, Chile, France, Germany, Spain, Italy, United
Kingdom, and United States. Twelve of the included studies were cross sectional,(32-41,
45, 49) two were prospective longitudinal studies,(43, 48) one was a retrospective
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study,(42) and six were randomized controlled trials(44, 46, 47, 50-52). Most of the
studies (16/21) only included children and adolescent participants, with five studies also
including adult participants.(32, 35, 37, 46, 50) There was a wide range of sample sizes,
with nine to 478 participants. Eleven different HRQL instruments were identified in the
literature review, which included: The Health Utilities Index 3 (HUI), EQ-5D-Y, EQ-5D3L, EQ-5D-5L, Autoquestionnaire Qualite´ de Vie Enfant Image (Portuguese version)
AUQEI, Short Form-36, PedsQL Neuromuscular module, PedsQL Generic Core module,
Peds-QL family impact module, Peds-QL Fatigue module, and a Likert scale survey of
six quality of life issues (Table 2-3). Most of the included studies provided general
descriptions of the HRQL scores in patients with SMA. However, some studies
performed additional stratified analyses. Thirteen studies compared the HRQL scores
between subgroups by SMA type, treatment groups, age, respiratory support, and the use
of a gastrostomy tube.(32-34, 36, 37, 39, 41-43, 46, 47, 50, 51) Five studies differentiated
HRQL score to functional or fatigue scores.(32, 35, 50) Lastly, nineteen studies included
a parent/caregiver proxy questionnaire, with five of those studies assessing the correlation
and agreement between the child’s scores and the parent/caregiver proxy scores (36-38,
43, 49); a detailed summary of each of the analyses are described below.(32-38, 41-52)
For the included studies, the clinical and family characteristics assessed and
correlated to the HRQL scores included: SMA type, age, ventilation support, use of
gastrostomy tube, fatigue scores, nusinersen use, functional measures, and treatment
groups. Thirteen studies assessed the HRQL scores by different subgroups including
SMA type, age, ventilation, ambulation, and treatment.(32-34, 36, 37, 39, 41-43, 46, 47,
50, 51) Five studies compared the PedsQL score by SMA type,(36, 37, 41-43) and two
studies compared EQ-5D-Y scores by SMA type.(33, 39) Belter et al. compared HUI
scores by SMA type, ventilation, and mobility. De Oliveira et al. compared AUQEI
scores by SMA type. Vega et al. compared PedsQL scores by SMA type, age, ventilation,
and Weaver et al. compared Peds QL scores by SMA type, and whether the patients
received respiratory support, had a gastronomy tube, were prescribed nusinersen and had
orthopedic interventions. Lastly, four studies compared PedsQL scores by the treatment
groups the participants were assigned to in the randomized controlled trial (RCT).(46, 47,
50, 51)
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Studies that compared HRQL in the SMA population to healthy
children and children with other conditions
Five studies compared HRQL in children with SMA to healthy cohorts.(32, 39,
41, 45, 49) Lopez-Bastida et al., Vega et al., Belter et al., and Iannaccone et al. compared
the scores of children with SMA to those of the general population, established from the
literature.(32, 39, 41, 49) Bach et al. compared the HRQL of participants with SMA to
their control group of healthy children.(45) Lopez-Bastida and Belter compared HRQL in
children with SMA to those with other conditions.(32, 39) Lopez-Bastida et al. compared
children with SMA to children with type 1 diabetes and Vega et al. 2020 compared
patients with SMA to patients with Duchenne’s muscular dystrophy (DMD).(39, 41)
In Lopez-Bastida et al., the estimated average EQ-5D social tariff score for
patients was 0.16. The score is significantly lower compared to young healthy Spanish
people between 16 and 20 years of age (0.987).(39) Additionally, the estimated average
EQ-5D social tariff score for SMA caregivers was only 0.49 while that of the general
population was 0.959. In Vega et al. 2020, the scores showed healthy peers reported a
PedsQL of 81.34 +/- 15.2, compared to the overall HRQL of 51.92 +/- 17 for patients
with SMA.(41) Iannacone et al. 2009 reported differences between the healthy children
sample and children with SMA.(49) Children with SMA and their parents report
statistically significant lower HRQL than healthy children. The greatest differences were
in the Physical Functioning Scale for both the child self-report and parent proxy-report.
Regarding the comparison of HRQL of patients with SMA to those with other
conditions, Lopez-Bastida et al. compared patients with SMA to patients with type 1
diabetes. They found the HRQL score for patients with SMA was significantly lower than
for those with type 1 diabetes (0.16 to 0.94 respectively).(39) Lastly, Vega et al. 2020
compared patients with SMA to patients with DMD.(41) The study found children with
DMD had a better HRQL compared to children with SMA in all PedsQL domains (total
score, disease, communication, and family). The authors hypothesized this may be
because DMD patients have greater independent mobility and verbal communication
until more advanced stages of their disease.

15

In conclusion, the included studies show that children with SMA have a
significantly lower HRQL compared to healthy children. It also appears that children
with SMA have a lower HRQL compared to children with other chronic conditions such
as type 1 diabetes and DMD.

Studies including both the parent/caregiver proxy and child reports
and how they are correlated
Most of the included studies reported on HQOL scores from a parent/caregiver
proxy (19/21). In four of the studies, the questionnaires were completed by the
parent/caregiver proxy if the child was too young and did not meet the age requirements
or were too highly dependent on their parents.(32, 33, 37, 41) Five of the studies assessed
the correlation and agreement between the child and parent/caregiver proxy scores.(3638, 43, 49)
In literature assessing the QoL in children, it is common for parents to act as a
proxy for their child if the child is unable to answer due to their age or disability.(21, 53)
The goal of a parent proxy-report is for the parents to assess what they believe are their
child’s own perceptions and feelings.(54) Four studies assessed only the parent proxyreport,(32, 33, 44, 45) where the parent or caregiver completed the questionnaire on
behalf of their child. Compared to fourteen studies that included parallel child self-report
and parent proxy-report.(35-39, 41-43, 47-52) However, only five of these studies
assessed the correlation and agreement between the child and parent proxy-reports.(3638, 43, 49)
Klug 2016 and Kocova 2014 did not note any significant differences in the child
self-report compared to the parent proxy HRQL.(37, 38) Klug et al. 2016 stated there
were no significant differences in the self and proxy evaluation of HRQL in patients with
SMA II or III (p > 0.05).(37) Comparisons of the individual questions showed good
agreement between the responses of the child and parent. There were only statistically
significant differences for two questions between the child and parent proxy.(38)
Alternatively, when Frognia et al. 2018 compared child and parents PedsQL
scores, a moderate or large discrepancy was found in five of the 51 families included in
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the study.(36) Weaver et al. 2020 compared the child self-report and parent proxy by
using a linear mixed effects model with family ID as the random effect.(43) They found
the child reported better HRQL compared to the parent proxy. Lastly, Iannaccone et al.
2009 reported moderate intraclass correlation coefficient (ICCs) between the parent and
child with the PedsQL questionnaires. The greatest overall agreement was found in the
PedsQL Total Generic Core module and “about my NM disease” module.(49) Overall,
there were mixed results regarding the differences between the self and proxy parent
HRQL reports. When assessing the agreement between the parent/caregiver and child
HRQL scores, it is important to note that children who are able to report their own HRQL
may be older, less cognitively impaired and less ill compared to children who are not able
to report their own HRQL.

Family and clinical characteristics associated with patients’ HRQL
scores as assessed by either the child and/or parent proxy
SMA Type
Some types of SMA can be very severe, leading to muscle weakness that may result in
respiratory, swallowing, and back muscle weakness. This in turn causes issues for
patients that may require ventilation support, a gastrostomy tube, or result in loss of
ambulation. When the PedsQL scores was assessed by SMA type, children with less
severe SMA types appeared to have better HRQL compared to those with more severe
SMA types. One study assessed the HRQL reported by families and patients and found
only four out of 42 parents of children with SMA type 2, and three out of nine parents of
children with SMA type 3 reported scores >80 in PedsQL.(36) In another study,189
patients/parents assessed the HRQL of patients with SMA, with 52% of respondents
being a parent proxy and 48% of the respondents being the patient. The study found
patients with SMA type 3 assessed their disease-specific HRQL as fairly high (selfreported), while patients with SMA type 1 had poorer proxy-assessed HRQL (69 vs. 34
on a scale with 0 = min. and 100 = max.; p < 0.001). There were no significant
differences in the self or proxy evaluations of HRQL in SMA 2 and 3.(37) In one study,
the authors retrospectively studied electronic medical records of 80 SMA patients, with
the aim of assessing the correlation between the reported HRQL using the PedsQL 4.0
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Generic Core module and PedsQL 3.0 NM module and the SMA type. A repeated
measures linear model was used to examine the PedsQL scores. All children with all
three types of SMA and their parents reported decreased scores on the PedsQL Generic
Core Scales and PedsQL NM module, with the most decreased scores among patients
with SMA type 1.(42) Weaver et al also reported significant differences using parent
proxy PedsQL Family Impact module with SMA types 1 and 2 in key functioning
domains (physical, emotional, social), family relations, family functioning, and parent
HRQL scales (all adjusted p <.03). For the PedsQL Neuromuscular module, the
communication domain was significantly different according to the SMA type for child
report, whereas the communication, family resources, and total score were significantly
different according to SMA type for the proxy-report.(43)
Two studies compared the EQ-5D-Y scores by SMA type. With an EQ-5D score
of 0 equivalent to death and 1 meaning perfect health, the average self-reported score of
patients with SMA in one study was 0.115, with children with SMA type 3 reporting the
highest score (SMA type 1 = 0.104, SMA type 2 = 0.067).(33) For the overall EQ-5D
VAS score, with 0 being the worst health you can imagine and 100 being the best health
you can imagine, the average self-reported score of patients with SMA was 66.24 (SMA
type 1= 59.25, SMA type 2= 67.46, SMA type 3 = 66.11).(33) In the other study, the
HRQL scores of the patients with SMA and their caregivers were assessed (time trade off
-TTO- social tariff, as well as the VAS).(39) The patients with SMA self-reported an EQ5D social tariff score of 0.16 (max. of 1), while the self-reported EQ-5D VAS was 54.1.
However, when considering only patients with SMA type 2, the mean self-reported EQ5D social tariff decreased significantly, obtaining a score equal to -0.012.
In contrast, two other studies found no differences in QoL and HRQL scores
when comparing children with different types of SMA.(34, 41) In an assessment of QoL
with the AUQEI Portuguese version, no differences were found when comparing selfreported scores from children with different SMA types. In the other study, the PedsQL
NM score which consists of the disease, communication, and family domains were
assessed in children with SMA type 1, 2, and 3. The parent proxy communication domain
score was lower in patients with SMA type 1 compared to SMA type 2 and 3, but not in
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the other PedsQL NM domains.(41) The total parent proxy PedsQL NM score was 46.5
for patients with SMA type 1 and 56.3 for patients with SMA types 2-3.
In summary, most of the included studies found an inverse relationship between
HRQL and the severity of SMA type, except for the study by De Oliviera and Vega.
However, the results found in that study may be explained by the different type of
questionnaire (AUQEI) used to assess HRQL.

Age
Two studies assessed whether the HRQL score differed according to the age of
the child with SMA.(35, 41) One study assessed whether the parent proxy-reported
PedsQL scores differed between children > 6 years and children ≤ 6 years and did not
find a significant difference.(41) Another study assessed whether an association between
age and perceived fatigue, for both child self-report and parent proxy-reports, was present
and also did not find a significant difference.(35)

Fatigue
To examine perceived fatigue, Belter et al. used the PROMIS fatigue SF parent
proxy instrument and found the scores in those with SMA were worse compared to the
general population and there did not appear to be a trend of scores varying by SMA type
or functional status.(32) Montes et al. conducted a randomized, controlled trial measuring
the effects of exercise on various outcomes, including fatigue as a secondary outcome.
(50) They used the PedsQL multidimensional fatigue score and noted, while both
children and parents reported good HRQL overall (83, 86.5 – on a scale of 0–100), the
children reported slightly lower levels of fatigue than their parents (85,74 – on a scale of
0–100).(50) Lastly, Dunaway et al. assessed fatigue using the PedsQL Multidimensional
fatigue score and the Fatigue Severity Score.(35) The results showed that all participants
with SMA reported perceived fatigue, and the child report of perceived fatigue was
similar to the parent proxy. They also found that perceived fatigue was similar between
participants with SMA type 2 and 3 (PedsQL Fatigue score: 70.2% vs. 73.4%) and was
not associated with function, HRQL, or fatigability in ambulatory patients with SMA.
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(35) There were also no associations between age and ambulatory status and perceived
fatigue, with all correlations having alpha levels of p > 0.05.
Overall, the studies assessing perceived fatigue in the SMA population all agreed
that fatigue scores in this population were worse compared to the general population.(32,
35, 50) Two studies also noted perceived fatigue was not affected by the SMA type and
functional status, although the studies used different measures (PROMIS fatigue SF and
PedsQL Fatigue).(32, 35) There were discrepancies regarding whether the perceived
fatigue scores were similar between self and parent proxy-reports.

Nusinersen
As previously mentioned, Nusinersen is a medication that is used to treat SMA
where it is administered by injection into the fluid surrounding the spinal cord.(6) Three
studies assessed whether the use of Nusinersen affects the HRQL.(43, 44, 47)
Both Chiriboga et al. and Weaver et al. did not find a significant difference in the
PedsQL score between those on Nusinersen compared to placebo. Chiriboga et al. found
a slight improvement for the PedsQL Generic Core scales for the 9 mg group at day 85
compared to baseline for both child self-reported and parent proxy-report.(47) Similarly,
a slight improvement for the Peds QL NM was observed for baseline compared to the 9
mg group with the change being greater for patient self-report compared to the parent
report, however neither were significant. No meaningful changes in the HRQL scores
were seen in other dose groups.(47) Weaver et al. noted both child and proxy-report
HRQL scores were better for children receiving nusinersen compared to children on
placebo, although this was not statistically significant.(43) Alternatively, the family
impact scales, and parental HRQL were both better for families of children not receiving
nusinersen.
Montes et al. assessed PedsQL parent proxy scores in a nusinersen treatment
group compared to placebo. The PedsQL Generic Core total score improved from
baseline for children treated with nusinersen, with a mean change score of 2.3 (-1.08,
5.72), whereas the PedsQL NM score stabilized over time -0.2 (-3.79, 3.49).(44)
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In summary, results from the included studies show mixed results in HRQL of those
taking nusinersen compared to those not taking nusinersen.

Ventilation Support
Weaver et al. found that ventilation support impacted both child self-report and
parent proxy-report of HRQL.(43) On the PedsQL NM module, QoL was rated better by
self-report for children without positive pressure ventilation support (68.2 vs. 55.9, P=
0.97) than by proxy-report (61.8 vs. 50.5, P = 0.029).

Gastrostomy Tube
Weaver et al. showed that the self-reported HRQL from the PedsQL NM module
score was significantly better for children without a gastronomy tube compared to those
who were gastronomy tube fed (68.2 vs. 48, P = 0.041). The parental proxy score of the
child’s HRQL for those without the gastronomy tube also appeared to be better (61.3 vs.
41.6, P =0.001).(43)

Functional Measures
Five studies assessed the correlation between clinical measurements and HRQL
scores.(34-36, 50, 51) Frongia assessed the correlation between the PedsQL with
functional scales such as the Egen Klassifikation 2 (EK2), Hammersmith Functional
Motor Scale Expanded (HSMSE) and RULM. (36) Their results showed that regardless
of the functional motor outcome, children and adolescents with SMA, as well as their
parents, have a perception of relatively good HRQL. Dunaway compared PedsQL and
short form scores with fatigue and function scores, which showed the Peds QL NM child
and parent report did not correlate to the function tests (Hammersmith or six-minute walk
test) (all correlations had alpha levels of p > 0.05). They also found no association
between ambulatory status and perceived fatigue.(35) De Oliveria compared AUQEI
child reported scores to functional status (measured by Hammersmith functional score),
and no significant difference was found when comparing QoL to the functional score.(34)
Finally, Swoboda et al. found the parent proxy HRQL scores did not improve as the
modified Hammersmith Functional Motor Scale (MHFMS) improved, but there was
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evidence of deterioration in HRQL as the Hammersmith score declined.(51) Therefore,
none of the studies found a significant relationship between functional status and HRQL
of patients with SMA.

Treatment Groups
Four RCTs assessed HRQL as a secondary outcome using PedsQL. Three of the studies
used both the child self-reported and parent proxy PedsQL scores according to their
intervention group.(46, 50, 51) All three studies were randomized, placebo-controlled
trials, assessing various interventions such as olesoxime, exercise, or l-carnitine and
valproic acid. One study assessed the child self-reported and parent proxy PedsQL score
according to the different dose groups of the nusinersen drug (1 mg, 3 mg, 6 mg, 9
mg).(47) None of the studies found a significant difference in the PedsQL score between
the treatment and control, or dose groups.

2.4 Discussion and Limitations of Previous Studies
The current literature is a useful starting point to assess the QoL and HRQL in
children with SMA. There were a few notable points of agreement among the included
studies in the literature review. First, the included studies did not find a difference in
HRQL for nusinersen use, ventilation support, or functional score status. Although the
studies agreed on these points, only two small studies assessed the relationship between
nusinersen and HRQL, and the ventilation studies focused more on the HRQL of the
parents as opposed to the HRQL of the children. Secondly, most of the studies agreed the
HRQL of patients were impaired across all PedsQL modules and patients with SMA have
lower HRQL scores compared to healthy children. Lastly, the studies found an inverse
relationship between HRQL scores and the severity of SMA.
There were also some important points of disagreement across the included
studies. First, findings were inconsistent regarding the agreement between the child’s
HRQL score and the parent proxy HRQL score. Some studies did not note any significant
differences in the child self-report compared to the parent proxy HRQL, however some
studies reported the child self-reported QoL was higher compared to scores reported by
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the parent proxies. Secondly, data regarding fatigue in the SMA population and its
association with HRQL were scarce and inconsistent. There were discrepancies between
whether the perceived fatigue scores were similar between self and parent proxy-reports
and, although two studies assessed associations between age and ambulatory status and
perceived fatigue scores, they used different fatigue measurements (PROMIS fatigue and
PedsQL Fatigue). None of the studies assessed an association between HRQL scores and
fatigue scores.
There were some consistent shortcomings of the studies identified in this
literature review. The first challenge is the interchangeability of the HRQL and QOL
terminology in the published literature. Although some studies use the term QOL, the
measurement that is used in the study is actually assessing HRQL. There needs to be a
consistent terminology adopted and linked clearly to the construct of HRQL that is
distinct from QOL. Secondly, although some studies compared HRQL scores by clinical
factors such as age, SMA type, ventilation status etc. there was a lack of studies using a
multivariable regression to assess the relationship between independent variables of
various types and HRQL in children with SMA. Lastly, all the studies were crosssectional studies, which limits the ability to make longitudinal observations and assess
HRQL temporality related to disease factors and make casual inferences.

2.5 Conclusion
Given the current discrepancies and limitations in the literature regarding the
HRQL of children with SMA, further comprehensive studies are required to examine the
HRQL in both the children self-report and parent proxy-reports using validated
questionnaires. Such studies would allow clinicians and researchers to gain more insight
into the factors associated with HRQL in children with SMA and identify potential risk
factors related to low HRQL and intervene, hopefully resulting in better outcomes for
children with SMA. The current discrepancies and limitations found in the literature
review helped guide the main objectives of my project.
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Table 2-1 Systematic Literature review: Table of Excluded Studies
Study
1.

2.

3.

4.

5.

6.

7.

8.

9.

Reason for exclusion

Benini F, Salamon E, Divisic A, Maghini I, Agosto C.
Acknowledging Limits: Statistics and the Child's
Quality of Life in Spinal Muscular Atrophy. Journal of
Paediatrics and Child Health. 01 Jun 2020;56(6):995996.
Brown L, Hoffman K, Krosschell K, et al.
REGISTRIES, CARE, QUALITY OF LIFE,
MANAGEMENT OF NMD: P.341 Use of the
assessment of caregiver experience with
neuromuscular disease (ACEND with SMA) - a
caregiver experience from a single center.
Neuromuscular Disorders. October 2020;30
(Supplement 1): S145-S146.
Dunaway S, Montes J, Kramer S, Podwika B, Rao A,
De Vivo D. Perceived fatigue and physiological fatigue
in spinal muscular atrophy (SMA): Are they related?
Neurology Conference: 66th American Academy of
Neurology Annual Meeting, AAN. 2014;82(10 SUPPL.
1)
Johnson NB, Paradis AD, Naoshy S, Montes J,
Krasinski DC. Impact of Caregiver Experience and
Hrqol in Later-Onset Spinal Muscular Atrophy (Sma):
Results from the Phase 3 Cherish Trial. Value in
Health Regional Issues. October 2019;19
(Supplement): S76.
Johnson NB, Paradis AD, Naoshy S, Wong J, Montes
J, Krasinski DC. Evaluation of nusinersen on impact of
caregiver experience and hrqol in later-onset spinal
muscular atrophy (SMA): Results from the phase 3
cherish trial. Neurology Conference: 72nd Annual
Meeting of the American Academy of Neurology, AAN.
2020;94(15 Supplement)
Kaltsa A, Hantzara V, Barbaresou C, Tsipou H,
Kolaitis G. Impact of neuromuscular diseases upon
health-related quality of life of children and
adolescents: A Greek cross-sectional study. European
Child and Adolescent Psychiatry. June 2011;20(1):
S206-S207.
Lloyd AJ, Thompson R, Gallop K, Teynor M.
Estimation of the quality-of-life benefits associated
with treatment for spinal muscular atrophy.
ClinicoEconomics and Outcomes Research. 2019;
11:615-622.
Sakai S, Maki M, Sakai N, Sudoh A, Kato M, Saitoh S.
Questionnaire survey conducted on the parents of
patients with spinal muscular atrophy type 1 in Japan
regarding switch devices, language development,
upper extremity function and QOL. [Japanese]. No To
Hattatsu. November 2012;44(6):465-471.

Letter to the editor, not a study

Scott C, Swoboda KJ, Kissel JT. Comparing child and
parent-proxy responses regarding function and

Included the full text manuscript already (SMA
CARNIVAL TRIAL PART II: a prospective,

Only assessed caregiver scores on ASCEND

This is an abstract of an included study

Only assesses the HRQL of caregivers

Only assesses the HRQL of caregivers

Includes children with all different types of
neuromuscular diseases (Duchenne Muscular
Dystrophy, Becker Muscular Dystrophy and
type II Spinal Muscular Atrophy)

This is an economic study where experts
estimated quality of life weights or utilities for
different SMA states

Only assesses the HRQL of caregivers
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assessment of quality of life: report from SMA
CARNI-VAL clinical trial. 2009:58, Abstract no:
ORM‐F&S‐07.
10. von Gontard A, Rudnik-Schoneborn S, Zerres K.
Stress and coping in parents of children and
adolescents with spinal muscular atrophy. Klinische
Padiatrie. 2012;224(4):247-51.
11. Voos M, Polido G, Barbosa A, Favero F, Caromano F.
Visual, cognitive and motor skills in children with type
I spinal muscle atrophy. Neuromuscular Disorders.
October 2015;25(2): S196.

single-armed trial of L-carnitine and valproic
acid in ambulatory children with spinal
muscular atrophy)
Only assesses the stress and coping of
caregivers

12. Love D, Hicks R, Wei Y, Zapata Aldana E, Almobarak
S, Campbell C. P.218Utility based health related
quality of life in children and adolescents with spinal
muscular atrophy. Neuromuscular Disorders. October
2019;29 (Supplement 1): S130.
13. Lopez Bastida J, Pena-Longobardo LM, Aranda-Reneo
I, et al. Pro44 the Economic Impact and Health-Related
Quality of Life of Spinal Muscular Atrophy (Sma). An
Analysis across Three European Countries. Value in
Health. November 2019;22 (Supplement 3): S848S849.
14. Iannaccone ST, American Spinal Muscular Atrophy
Randomized Trials G. Outcome measures for pediatric
spinal muscular atrophy. Multicenter Study Research
Support, Non-U.S. Gov't Research Support, U.S. Gov't,
P.H.S. Validation Study. Archives of Neurology.
2002;59(9):1445-50.

This abstract is using data from the same survey
used in this thesis (Timepoint 1)

Main outcomes assess the visual, cognitive, and
motor skills in children with type 1 SMA. No
usable HRQL data

This is an abstract of an included study

The full patient population of this publication is
published in “reliability of 4 outcome measures
in pediatric spinal muscular atrophy”
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Table 2-2 Systematic Literature Review: Table of Included Studies
Study

Study Design

HRQL
measure(s)
HUI3

Sample
size (N)
478

1

Belter L et al
2020

Cross sectional

2

Chambers et
al 2020

Cross sectional
cohort

EQ-5D-Y and
CarerQoL (for
parents)

40

3

De Oliveira et
al 2011

Cross sectional
cohort

AUQEI
Portuguese
version

33

4

Dunaway et al
2019

Cross sectional
cohort

32

5

Frongia et al
2018

Cross sectional
cohort

PedsQL NM,
PedsQL
Fatigue scale
and short form36
PedsQL
Generic Core

6

Klug et al
2016

Cross sectional
cohort

PedsQL NM

189

7

Kocova et al
2014

Cross sectional
cohort

PedsQL NM

35

8

Lopez-Bastida
J et al 2017

Cross sectional
cohort

EQ-5D- 3L (for
proxy
caregivers)

81

9

PenaLongobardo
LM et al 2020

Cross sectional

EQ-5D-3L for
patients and
5Q-5D-5L for
caregivers

86

10

Kissel JT et al
2011

RCT

PedsQL
Generic Core

33

11

Vega P et al
2020

Cross sectional

Peds-QL NM

38

12

Wagner S et al
2020

Retrospective
study

Peds-QL NM
and Peds QL
Generic Core

80

51

Objective(s)
The survey assesses HRQL, loss of work
productivity and fatigue using the HUI,
WPAI and the PROMIS fatigue SF
To quantify the economic and health
related quality of life burden incurred by
households with a child affected by
SMA
To determine the level of quality of life
in a cohort of SMA children and
adolescents and study its relation to
motor ability.
To assess the relationship of perceived
fatigue to fatigability, function, and
quality of life in SMA in children and
adults with SMA and their caregivers
To describe the correlation between the
functional motor status with the
perceived quality of life by families and
patients
This study aimed at analyzing the
economic burden and disease specific
HRQL of patients with SMA in
Germany (children and adults)
To improve the care for children with
spinal muscular atrophy in the Czech
Republic, we created a survey to obtain
the baseline information about their
quality of life and compared the data
with equivalent data from the United
States
The aim of this study was to determine
the economic burden and HRQL of
patients (children/adolescents) with
SMA and their caregivers in Spain
This study aimed to estimate the
economic impact and health related
quality of life of patients with SMA in
three European countries (France,
Germany, and the UK)
The primary objective was to assess the
safety, tolerability, and efficacy of a
combined regimen of oral VPA and
carnitine in SMA patients 2–17 years of
age
To characterize QoL in a sample of
Chilean children and adolescents with
SMA
The aim of the study is to compare
HRQL among patients with different
types of SMA
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13

Weaver MS et
al 2020

Prospective,
longitudinal,
crossover
survey

Peds-QL NM,
Peds-QL
Family impact
module

58

14

Bach JR et al
2003

Cross sectional

Likert scale
survey of QoL

54

15

Bertini E et al
2017

RCT

Peds-QL NM

160

16

Chiriboga CA
et al 2016

RCT

28

17

Iannaccone
ST et al 2003

Prospective
study

PedsQL
Generic Core
and NM
Peds NM

18

Iannaccone
ST et al 2009

Cross sectional

PedsQL
Generic Core
and NM

176

19

Montes J et al
2014

RCT

PedsQL NM
and PedsQL
Fatigue scale

9

20

Montes J et al
2020

RCT

Peds-QL
Generic Core
and Peds-QL
NM

63

21

Swoboda KJ
et al 2010

RCT

PedsQL
Generic Core

61

34

To report on the quality of life and
family experience for children with
SMA with attentiveness to patient and
proxy concordance and to stratify quality
of life reports by SMA type and medical
interventions
To compare healthcare professionals’
assessment of the quality of life of spinal
muscular atrophy type 1 children with
that of the care providers for the children
Investigated the safety and efficacy of
olesoxime in patients with type 2 or nonambulatory type 3 SMA
To examine the safety, tolerability and
PK of nusinersen in patients with
childhood SMA
To demonstrate that 4 outcome measures
are reliable for use in clinical trials in
patients with SMA
The aim of the study was to investigate
the feasibility, reliability, and validity of
the PedsQL NM and the PedsQL generic
core module in children with SMA
To assess the effects of exercise on
measures of function, strength, and
exercise capacity in ambulatory SMA
patients.
ACSCEND and PedsQL generic core
and neuromuscular module were
administered to caregivers of children in
the CHERISH and SHINE to assess the
effects of longer-term treatment with
nusinersen on caregiver impact and
HRQL
To assess potential benefit for improving
motor function in a young nonambulatory cohort of children with
SMA in a randomized double-blind
placebo controlled
clinical trial
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Table 2-3 Quality of Life Instruments Identified in Literature Review
Instrument
Health Utilities Index 3
(HUI3)

EQ-5D-Y

Included Domains
•
•
•
•
•
•
•
•
•
•
•
•

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Vision
Hearing
Speech
Ambulation
Dexterity
Emotion
Cognition
Pain
Mobility
Looking after myself
Doing usual activities
Having pain or
discomfort
Feeling worried, sad, or
unhappy
Family factors
Social factors
Activities
Health
Body functions
Separation
Physical functioning
Physical role
Pain
General health
Vitality
Social function
Emotional role
Mental health
Neuromuscular disease
Communication
Family resources

•
•
•
•

Mobility
Self-care
Usual activities
Pain/discomfort

•
Auto questionnnaire Qualite´
de Vie Enfant Image
(Portuguese version) AUQEI

Short Form-36

PedsQL Neuromuscular
Module

EQ-5D- 3L

Studies
Belter et al 2020

Chambers et al 2020

De Oliveira et al 2011

Dunaway et al 2019

Dunaway et al 2019
Klug et al 2016
Kocova et al 2014
Vega et al 2020
Wagner et al 2020
Weaver et al 2020
Montes et al 2014
Bertini et al 2017
Chiriboga et al 2016
Iannaccone et al 2003
Iannaccone et al 2009
Montes et al 2020
Lopez-Bastida et al 2017
Pena-Longobardo et al 2020
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EQ-5D-5L

PedsQL Generic Core
Module

Peds-QL Family Impact
Module

Peds-QL Fatigue Module

Likert scale survey of QoL

•
•
•
•
•
•
•
•
•
•

Anxiety/depression
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
Physical functioning
Emotional functioning
Social functioning
School functioning

•
•
•
•
•
•
•
•
•
•
•

Physical functioning
Emotional functioning
Social functioning
Cognitive functioning
Communication
Worry
Daily activities
Family relationships
General fatigue
Sleep/rest fatigue
Cognitive fatigue

No Domains

Pena-Longobardo et al 2020

Frongia et al 2018
Wagner et al 2020
Montes et al 2020
Chiriboga et al 2016
Iannaccone et al 2009
Swoboda et al 2010
Kissel et al 2011
Weaver et al 2020

Montes et al 2014
Dunaway et al 2019

Bach et al 2003
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Chapter 3
3.0 Methods
3.1 Data Source
This chapter gives an overview of the source of the study data, ethics approval,
the eligibility criteria, data collection procedures, an overview of the measures collected
in the questionnaires, and lastly the statistical analyses used to address the objectives.
Study participants were recruited through the Canadian Neuromuscular Disease
Registry (CNDR), a Canada-wide clinic-based registry of people diagnosed with a NM
disease. The CNDR collects demographic and medical information on patients in Canada,
with the goal of improving the understanding of NM therapies and accelerating the
development of effective therapies.(55, 56) The CNDR consists of 36 clinical sites in 15
academic centers across Canada. To date, 4310 patients have been recruited from the 10
provinces and 3 territories across Canada. Patients are usually consented to participate
through affiliated clinics across Canada, or in some cases, can self-register through the
National office.(55) To be eligible for inclusion into the CNDR, the patient must have a
confirmed diagnosis of a NM disease and provide informed consent.(56) When patients
or their parent/caregiver (if patients are < 18 years) register for the CNDR, they are
notified of clinical trials they or their child may qualify for, new scientific advancements,
therapy access, and any survey-based research studies.(57)
There are currently 229 SMA patients in the registry, accounting for 5.3% of the
total participants in the CNDR. Fifty-four percent (N=125) of those SMA patients are
pediatric. Based on published prevalence estimates, the CNDR currently has an
ascertainment of 38.1% of adult and pediatric SMA patients in Canada.(55) The CNDR
supports different types of projects including clinical trial feasibility and planning, trial
notifications, survey and questionnaire-based studies, data analysis, and other
informational mail-outs.(55) Previous studies published from the CNDR database include
clinical outcomes in DMD,(58) the relationship between QoL and HRQL in males with
DMD,(59) fatigue in children with DMD,(60) and a multi-source approach to determine
SMA incidence and research ready populations,(61) to name a few.
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3.2 Ethics
The ethics approval for the study was obtained from both Western University’s
Health Sciences Research Ethics Board and approval was given by the CNDR research
advisory committee.

3.3 Eligibility
All 77 parent/caregivers of a child diagnosed with SMA, along with their affected child
between the ages of 0 and 18 years, who consented to being a part of the CNDR and
indicated they were interested in research opportunities were contacted. The inclusion
and exclusion criteria for the study are listed below.
Inclusion criteria:
1. Patients with a confirmed genetic diagnosis of SMA
2. Enrollment in the CNDR and the parent has indicated interest in research studies
3. The availability of the parent or caregiver to complete a parent proxy
questionnaire
Exclusion criteria:
1. The presence of comorbidities unrelated to SMA
2. The inability to adhere to the study protocol, due to cognitive impairment or lack
of language skills required to complete the questionnaire
3. Patients involved in any long-term study with Nusinersen

3.4 Data Collection
The CNDR mailed out a Letter of Information (Appendix C), assent form
(Appendix C), set of questionnaires, and a token of appreciation ($10.00 gift card) to all
eligible parent/guardians in the database who had a child diagnosed with SMA and
indicated they were interested in participating in research. Overall, there were a total of
77 eligible families who met the inclusion criteria, out of 125 patients in the registry. To
protect their confidentiality, a unique study number was generated by the CNDR staff and
added to the questionnaire prior to being sent out, with only the CNDR national staff able
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to link questionnaire responses to identifying information and not our local research
team.
Questionnaire packages were compiled in London, Ontario and sent to the national office
of the CNDR to be mailed out in August 2018. The questionnaire booklets for both the
child and parent/guardians were distributed according to the ages of the child. Only
children who were five and older were sent their own questionnaires to complete (N =
63); if the child was younger than five years of age (N = 14) they were not sent their own
questionnaires. All parents, regardless of child’s age, were sent parent/caregiver version
of the questionnaire.
Therefore, only the responses related to the group of older children (≥ 5 years) will be
used to examine the agreement between the child reported and parent/caregiver proxy
HRQL scores. The parent and child were instructed to independently complete the
questionnaires.
The questionnaire booklets were categorized into five different categories, based on
child’s age. Although the content of the in the questionnaires is assessed all the same
concepts, the language for each of the age groups was modified to be age appropriate.
The age groups included:
1. Infant questionnaire (Only parent/caregiver proxy questionnaire) (N= 1)
2. Toddler questionnaire (2-4 years) (Only parent/caregiver proxy questionnaire) (N
= 13)
3. Young child questionnaire (5-7 years) (child self-report and parent/caregiver
proxy questionnaires) (N = 12)
4. Child questionnaire (8-12 years) (child self-report and parent/caregiver proxy
questionnaires) (N = 26)
5. Teen questionnaire (13-18 years) (child self-report and parent/caregiver proxy
questionnaires) (N = 25)
The parent/guardian was asked to complete the questionnaires about their child, without
consulting their child. The child was asked to independently complete their own
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questionnaire. If the child was unable to independently complete their questionnaire, the
parents were instructed to read the questions to their child verbatim and not guide the
child when answering their question. The full instructions for both the parents and child
are located in the APPENDIX D-F. Implied consent and assent were assumed if the
parents mailed back the questionnaires.
A modified Dillman’s Tailored Design method (TDM) was used when designing the
survey methodology. This method was implemented to maximize the response rate of the
participants. Based on the principles of TDM, a reminder postcard was mailed out to all
families one week after the initial questionnaires were mailed (Appendix G). Finally, a
month after the initial mail-out another reminder package (minus the token of
appreciation) was sent to those families who still did not respond (Appendix H). A
member of the CNDR or the CNDR coordinator from the clinic where the participant was
enrolled followed-up by telephone, for the participants who did not respond (Appendix
I).
Questionnaires were initially returned to the CNDR office at the University of Calgary,
Alberta, Canada. The questionnaires were then forwarded from Calgary to Children’s
Hospital in London, Ontario where the information from the questionnaires was entered
into REDCap and exported into SAS for data analysis. Data verification was performed,
where data from 50% of the questionnaires were double checked for accuracy in
REDCap.

3.5 Measures
Children with SMA and their parents completed the PedsQL questionnaires that
assessed child HRQL (Table 3-1). Children completed the PedsQL 4.0 Generic Core
module, PedsQL 3.0 NM module, and PedsQL 3.0 Fatigue module. Parents completed
the PedsQL 4.0 Generic Core module, PedsQL 3.0 NM module, and the PedsQL 3.0
Fatigue module. In addition, the parents also answered questions regarding family and the
child’s clinical characteristics. The measures are described in detail below.
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Pediatric Quality of Life (PedsQL) Questionnaire
The PedsQL questionnaire was used to measure the HRQL of the children with
SMA in the current study. It is a HRQL instrument designed for both children and
adolescents and integrating generic core scales with disease specific scales into one
instrument.(62, 63) It is a reliable and valid measure to assess the HRQL in both healthy
children, as well as those with acute and chronic conditions, including SMA.(48, 49, 6368) The PedsQL 1.0 was originally derived from the Pediatric Cancer database and
utilized non-categorically.(69) However, the PedsQL has developed over the years to the
2.0 and 3.0 versions to include additional constructs, a more sensitive scaling range, and a
wider range for patient and parent proxy-report.
The PedsQL measures both the patients’ and parents’ perceptions of the patients’
HRQL as defined in terms of the impact of disease and treatment on an individual’s
physical, psychological, and social functioning, and disease treatment/specific symptoms.
(69) There are different versions of the PedsQL questionnaire depending on the age of the
child. The three different versions include: the young child questionnaire, child
questionnaire, and teenager questionnaire. The forms are similar, however the
questionnaires for the younger children are more simply worded.(69) The parent
questionnaire is the same as the child/adolescent questionnaire, but in third person tense
(Varni et al. 1999).(69) Each specific PedsQL module contains different domains with
their own questions and each question is measured on a five-point Likert scale from 0-4
(0=never, 1=almost never, 2=sometimes, 3=often, 4=almost always). All the questions
are reverse scored and linearly transformed into a scale out of 100, where 0=100, 1=75,
2=50, 3=25, 4=0. Therefore, lower scores indicate a worse HRQL, and higher scores
indicate a better HRQL. If more than 50% of the items in the scale are missing, the scale
scores are not to be calculated.
This study used the generic core module, the NM module, and the fatigue module for
both children and parent proxy. Each PedsQL module is further explained in detail below
and an example of the questionnaires can be found in the Appendices J-M.
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PedsQL 4.0 Generic Core Module
The PedsQL 4.0 Generic Core module is a multidimensional child self-report and
parent proxy-report, developed to be integrated with the PedsQL disease specific modules
(Appendix J).(62, 63) This module was designed to assess the differences between
healthy children and pediatric patient with both acute or chronic health conditions.(63) It
has been used on over 35,000 healthy children and children with a variety of pediatric
health conditions.(49) The child self-report includes different forms designed for
children ages 5-7 years, 8-12 years, and 13-18 years.(63) The parent proxy-reports
include forms designed for parents with children from ages 2-4 years (toddler), 5-7 years
(young child), 8-12 (child), and 13-18 (adolescent). The items for each of the age forms
are almost identical, with the minor differences due to the appropriate language for that
age category. For the toddler age range (2-4 years) there is no self-report form for the
child, due to the developmental limitations’ children under 5 years of age. The young
child report is scored on a 3-point Likert scale (0=Not at all, 2=Sometimes, 4= A lot) for
ease of interpretation and the rest are scored on a 5-point Likert scale (0= never,
4=almost always). The generic core module consists of 23 items, divided into four
separate categories including physical functioning (8 items), emotional functioning (5
items), social functioning (5 items), and school functioning (5 items).
The PedsQL 4.0 Generic Core module can be scored a couple of different ways
in addition to the overall and domain scores. The psychosocial health summary score can
be derived from the sum of the emotional, social, and school functioning scales, and the
physical summary score is equivalent to the physical functioning score.

PedsQL 3.0 Neuromuscular Module
The PedsQL 3.0 NM module was developed to assess the HRQL in children with
NM disorders including SMA (Appendix K).(49) Similar to the generic core module, the
NM module also reports parallel child self-report formats for ages 5-7 years, 8-12 years,
and 13-18 years and parent/caregiver report formats for ages 2-4 years, 5-7 years, 8-12
years, and 13-18 years.(49) The NM module was developed using the authors’ research
and clinical experiences with NM disorders including SMA and DMD, along with other
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chronic pediatric conditions. The authors used the same methodology used to develop
other Peds QL disease specific modules (i.e., arthritis, cancer, diabetes etc.).(49) The
PedsQL 3.0 NM module consists of 25 items, divided into three different categories
including about my NM disease (17 items), communication (3 items), and family
resources (5 items). The young child report only consists of the 17 items “About my NM
disease scale” and does not contain the “Communication” and “About our family
resources” scales since the authors found the coefficient alphas on these two scales to be
in the unacceptable range for children 5-7 years.(49) The parent report for ages 2-18
years includes all 3 dimensions and all 25 items. The PedsQL 3.0 NM can be scored
either by dimension or the overall score.

PedsQL 3.0 Fatigue Module
Lastly, the PedsQL 3.0 Multidimensional Fatigue module is a generic symptom-specific
instrument measure child and parent perceptions of fatigue in pediatric patients
(Appendix M).(67, 70) The multidimensional constructs were derived from literature
reviews of both the adult and pediatric populations and incorporated into the PedsQL
measurement model. (70) Similar to the Generic core and NM modules, the Fatigue
module comprises the child self-report and parent proxy-report formats. The parent
proxy-reports are parallel to the child self-report forms and are designed to assess the
parent’s perceptions of their child’s fatigue. (70) The parent proxy-report also includes
the toddler age range (2-4 years), which does not include a self-report form due to the
developmental limitations of the child.(70) The PedsQL 3.0 Fatigue module is composed
of 18 items, categorized into three dimensions including general fatigue (6 items),
sleep/rest fatigue (6 items), and cognitive fatigue (6 items). The PedsQL 3.0 Fatigue
module can be scored either by dimension or the overall score. Items were marked on a
3-point scale from 0-4 (0= Not at all, 2 = sometimes, 4= a lot) for the young child report
for ease of interpretation, and items were marked on a 5-point Likert scale from 0-4 for
the other child and parent proxy-reports.
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Clinical Information
Additional clinical information was assessed in the parent questionnaires (Appendix N).
The information included the SMA type, ambulatory status (yes or no), scoliosis status
(yes or no), use of assisted ventilation (none, tracheostomy/ventilation, non-invasive
bilevel positive airway pressure (Bi-PAP) machine, other), and medications the child is
currently receiving (i.e., Nusinersen/Spinraza, salbutamol, valproate, gabapentin,
nutritional supplements, and any other medications/supplements or investigational
products).

Family Characteristics
The child and family characteristics and sociodemographic information were also
collected in the parent questionnaire (Appendix N). The socio-demographics information
included the parent’s highest level of education, current work status, current marital
status, partner’s work status, total yearly household income and main sources of income.

Clinical Expertise
Given that the sample size was relatively small and there was limited pre-existing
literature on what to base variable selection on for regression modelling, it was felt a
clinical perspective would be important to inform the selection of variables. A meeting
was held with five neurologists (CC, MH, CS, HM, KS) with experience treating children
with SMA. A list of the clinical and family demographic factors collected from our
questionnaire, along with the results from the literature review were presented to them.
Based on this information, the clinicians were asked to rank these characteristics in terms
of importance to patients’ HRQL. Overall, the top factors selected included: family
income, fatigue, ventilation status, and ambulatory status. This meeting was helpful to
determine the variables the clinicians believed to be most associated with a child’s
HRQL, based on their clinical experience. This information was then used to confirm the
variables that should be included in the final regression models.
The clinicians thought annual family income was important because it determines
whether the families can afford general life expenses that may improve the patients
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HRQL. The clinicians included fatigue because it has been significantly associated with
other pediatric NM conditions, such as DMD. Lastly, ventilation status and ambulatory
status were included as a marker of the patient’s disease severity and independence.
SMA type was not included because the diagnosis of the SMA type is dependent on the
child’s best motor status, which is usually determined early in life after it is relatively
constant. Therefore, children with type 1 SMA who survive infancy, children with type 2
SMA and type 3 SMA who lose ambulation, are all similar enough that other factors such
as lung function and ambulation are the major differentiating disease severity factors.
Furthermore, it is becoming less important given the disease modifying therapies now
available which are changing the trajectory of the disease. Lastly, nusinersen use was also
not included because the clinicians felt that regardless of treatment with nusinersen, it is
less important than the impact it had on the motor function, such as ambulation and
breathing.

3.6 Statistical Analyses
Statistical Analyses were performed with SAS software version 9.4. A two-sided p value
of less than 0.05 was considered statistically significant for all tests. Below are the
statistical approaches used to assess the three objectives of this thesis.

Objective 1: To describe the HRQL in children with SMA
from the children’ and parents’ perspective
The mean, median, standard deviation, and range of child reported and
parent/caregiver proxy-reported HRQL scores for children with SMA were
computed for the total score and sub-scores for the following PedsQL
modules: 1) PedsQL 4.0 Generic Core module (sub scores include: physical,
psychosocial, emotional, social, school); 2) PedsQL 3.0 NM module (sub
scores include: NM disease, communication, family resources); and 3)
PedsQL 3.0 Fatigue module (sub scores include: general fatigue, sleep/rest
fatigue, cognitive fatigue).
As a reference, the self-reported and proxy-reported HRQL scores of children
with SMA were compared to similar-aged healthy children and children with

38

another chronic NM disease (Duchenne Muscular Dystrophy), along with
their parent/caregiver proxy scores using published data. Unpaired t-tests were
performed between the child reported and parent/caregiver proxy-reported
scores of children with SMA, to the child reported and parent/caregiver proxyreported scores of similar-aged healthy children and children with DMD.

Objective 2: To examine the agreement between child
reported and parent/caregiver proxy scores in older
children with SMA
To examine the agreement between the child reported (≥ 5 years) and
parent/caregiver proxy scores. Paired t-tests and ICC analyses were performed
to examine differences between the child self-reported and parent/caregiver
proxy scores. This was computed for both the total score and sub scores of the
following PedsQL modules: 1) PedsQL 4.0 Generic Core module (sub scores
include: physical, psychosocial, emotional, social, school); 2) PedsQL 3.0 NM
module (sub scores include: NM disease, communication, family resources),
and 3) PedsQL 3.0 Fatigue module (sub scores include: general fatigue,
sleep/rest fatigue, cognitive fatigue).

Objective 3: To explore associations between both the
child reported and parent/caregiver proxy HRQL scores
to clinical and family characteristics in younger and
older children with SMA
To explore the association between the child reported and parent/caregiver
proxy HRQL scores (PedsQL 4.0 Generic Core module and PedsQL 3.0 NM
module) with the clinical and family characteristics in children with SMA.
Due to the small sample size and exploratory nature of this objective, a
combination of a literature review, clinical expertise, and bivariate analyses
were used to determine the variables to include in the final regression models.
For a variable to be included in the final regression model, it would have to be
1) assessed as significantly associated to the child reported and
parent/caregiver proxy HRQL scores based on the bivariate analysis and 2)
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identified as relevant in either the literature review or informed by the meeting
of clinical experts.
Bivariate analyses were performed to assess associations between clinical and
family characteristics and child reported and parent/caregiver proxy-reported
PedsQL 4.0 Generic Core and PedsQL 3.0 NM module scores. For
dichotomous variables (ambulatory status, scoliosis status, use of approved
medications, and use of non-approved medications), unpaired two-sample ttests or non-parametric Wilcoxon Rank Sum tests were computed to assess for
differences in the PedsQL 4.0 Generic Core and PedsQL 3.0 NM scores
between categories. The Wilcoxon Rank Sum tests were used if n<30 in one
of the categories, or if the PedsQL score violated the normality assumption.
For categorical variables of more than two categories (SMA type, ventilation
support, parental education, parental work status, parental marital status, and
total household income), one-way ANOVA or a non-parametric KruskalWallis tests were used. The Kruskal-Wallis tests were used instead of the oneway ANOVA when n<30 in one or more categories, or when the PedsQL
score violated the normality assumption. The distributions of continuous
variables were assessed using graphical methods such as the normal quantilequantile plots, box and whisker plots, and histograms. Statistical analyses for
normality were also performed using the Shapiro-Wilk test of normality.
The relationships among the continuous variables (age, PedsQL 3.0 Fatigue
module) and the PedsQL 4.0 Generic Core and PedsQL 3.0 NM module
scores were first visually assessed using scatter plots. Pairwise comparisons
between the continuous variables and the PedsQL scores were examined with
Pearson’s correlation coefficient (r) for normally distributed data, or
Spearman’s rank correlation coefficient (p) for non-normally distributed data.
Multivariable linear regression analyses were used to explore the associations
of the clinical and family characteristics to both the child reported and
parent/caregiver proxy-reported scores PedsQL scores. For a variable to be
included in the final multivariable linear regression, it had to be considered
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significant (p <0.10) based on the bivariate analysis and suggested in either
the clinician assessment or literature review as relevant (Table 4-9).
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Table 3-1 Child and Parent QoL and HRQL Measures
Questionnaire
PedsQL 4.0
Generic Core

Sections

Physical functioning,
Emotional functioning,
Social functioning, and
School functioning
PedsQL 3.0
About my
Neuromuscular neuromuscular disease,
Module
Communication,
Family resources
PedsQL
General fatigue,
Fatigue
Sleep/Rest Fatigue,
Module
Cognitive Fatigue
PedsQL 2.0
Physical functioning,
Family Impact Emotional functioning,
Module
Social functioning,
Cognitive functioning,
Communication,
Worry, Daily
activities, Family
relationships

Single item or
Parent
multidisciplinary and/or child
Multidisciplinary Both

Items

Multidisciplinary

Both

25 items

Multidisciplinary

Both

18 items

Multidisciplinary

Parent

36 items

23 items
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Chapter 4
4.0 Results
4.1 Sample Descriptive Statistics
The initial part of this chapter provides a description of the clinical and demographic
characteristics of the sample, reports information regarding missing data, and includes an
assessment of the responder and non-responder characteristics. The second part of this
chapter reports on the results pertaining to the three objectives of the thesis.
Seventy-seven eligible families were identified from the CNDR and sent questionnaires
in 2018. Of these, 46 eligible families returned their completed questionnaires, resulting
in an overall response rate of 59.7% (46/77). One of the responder families was
subsequently excluded due to an ineligible diagnosis (distal SMA), leaving 45 included
families (Appendix O). Both the parent and child questionnaires were completed in 33
families and 12 families completed the parent questionnaire. For the 12 families that only
completed the parent questionnaire, eight of the children were too young (< 5 years) to
complete their own questionnaires and four children chose not to return their
questionnaires. Univariate analyses were used to examine characteristics of the sample
(mean, median, and standard deviation (SD) for continuous variables and frequencies for
categorical variables).
The children’s clinical and demographic characteristics are presented in Table 4-1 The
mean age of the patients with SMA was 9.9 years (SD 4.8) with eight (17.8%)
categorized as “toddler”, seven (15.6%) categorized as “young child”, 16 (35.6%) as
“child”, and 14 (31.1%) as “teen”. There were 10 (22.2%) children with type 1 SMA, 27
children (60.0%) with type 2 SMA, seven children (15.6%) with type 3 SMA, and one
child (3.8%) with type 4 SMA. Eight (17.8%) respondents were ambulatory and 22
(48.9%) were taking Nusinersen.
The demographic characteristics of the parents/caregivers of the children are presented in
Table 4-2. The mean age of parent respondents was 40.8 years (SD 10.1). The majority
of parent/proxy questionnaires were completed by the mother ([34/45] 75.6%), where
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most of the parents were married ([40/45] 88.9 %) and living with their spouse ([43/45]
95.6%).

4.2 Missing Data
The percent missing for each question in the PedsQL questionnaires ranged from 2% to
9% for the child reported scores, and 2% to 22% for the parent/caregiver proxy scores.
The main reason for the high missing percentage in parent/caregiver proxy scores were
due to the missed questions regarding running or walking in the PedsQL Generic Core
module. These questions may have been left blank since the child may not have been
ambulatory and the question may not have pertained to them. Unfortunately, the
questionnaire design does not have a ‘not applicable’ response, so for this study while we
assume it is left blank due to a high number of children not walking, we have described it
here as potentially missing data.
Computation of the PedsQL domain scores requires that at least half of the questions
must be completed to be considered not missing. The percentage of missing domains
scores ranged from 4% to 13% for parent/caregiver proxy and was 3% for the child
reported questionnaire. Similar to above, the domains with a higher missing percentage
were in the physical domain of the PedsQL Generic Core module, where the questions
may not have pertained to the child.
Lastly, there was minimal missing data from the questions on family and clinical
characteristics.

4.3 Comparison of Responders and Non-Responders
Aggregate information about the non-respondents was obtained from the CNDR
database. Bivariate analyses such as an independent t-test, chi square test of
independence (t- and X2), and fisher’s exact test of independence were performed to
determine whether non-respondents differed from respondents, regarding their clinical
and demographic characteristics. Clinical characteristics of non-respondents were not
statistically significantly different from the respondents in any of the domains (Table 4-
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1). The non-responder information was taken from the patient’s registry database,
whereas the responder information was taken from the respondents’ questionnaires.

4.4 Objective 1 Results: To describe the HRQL scores in
children with SMA from the children’ and parents’
perspective
Child self-report
The child reported PedsQL 4.0 Generic Core (sub scores include: physical, psychosocial,
emotional, social, school), the PedsQL 3.0 NM module (sub scores include: NM disease,
communication, family resources), and the PedsQL Fatigue module (sub scores include:
general fatigue, sleep/rest fatigue, cognitive fatigue) mean, median, SDs, and ranges are
presented in Table 4-3. The PedsQL scores for the physical domain scores were the
lowest and the fatigue total, fatigue domain scores, and emotional domain scores were the
highest.
PedsQL scores from similar-aged healthy children and children with DMD were used as
a reference (Table 4-4).(59, 60, 63) Un-paired t-tests were conducted to assess the
differences between the scores from similar-aged healthy children and children with
SMA. The healthy child self-reported sample consisted of 209 to 401 (depending on the
questionnaire) participants who were assessed in either physicians’ offices during checkups or by telephone. Compared to the similar-aged healthy children, children with SMA
reported significantly lower scores for the total PedsQL 4.0 Generic Core module (p <
0.001), the PedsQL 4.0 Generic physical summary score (p < 0.001), the PedsQL 4.0
Generic psychosocial summary score (P < 0.001), the PedsQL 4.0 Generic social
summary score (P < 0.001), the PedsQL 4.0 Generic school summary score (P = 0.006),
the total PedsQL 3.0 Fatigue module (P = 0.004) and the PedsQL General Fatigue
summary score (P = 0.001). However, there were no significant differences between the
similar-aged healthy children and children with SMA for the PedsQL 4.0 Generic
emotional summary score, PedsQL 3.0 Fatigue sleep/rest fatigue and PedsQL 3.0
cognitive fatigue summary scores (Table 4-4).
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Un-paired t-tests were also conducted to assess the differences between the scores from
similar-aged children with DMD and children with SMA. Children with SMA were
compared to children with DMD because it is another common degenerative
neuromuscular disorder in children. The DMD child self-reported sample consisted of 64
to 83 (depending on the questionnaire) participants, who were also recruited from the
CNDR as part of a different study. Compared to children with DMD, children with SMA
reported similar PedsQL 4.0 Generic Core, PedsQL 3.0 NM, and PedsQL 3.0 Fatigue
scores. However, children with DMD did report significantly higher PedsQL Generic
physical summary score (P = 0.004), PedsQL 3.0 total NM score (P = 0.04), and about
my NM disease summary score (P = 0.009) (Table 4-4).

Parent proxy-report
The parent proxy-reported PedsQL 4.0 Generic Core (sub scores include: physical,
psychosocial, emotional, social, school), the PedsQL 3.0 NM module (sub scores include:
NM disease, communication, family resources), and the PedsQL Fatigue module (sub
scores include: general fatigue, sleep/rest fatigue, cognitive fatigue) mean scores, SDs,
and ranges are presented in Table 4-3. The PedsQL scores for the physical domain were
the lowest while the total fatigue and sleep/rest and cognitive fatigue domain scores, and
emotional domain scores were the highest.
Un-paired t-tests were conducted to assess the differences between parent proxy scores
from similar-aged healthy children and parent proxy scores from children with SMA. The
parent proxy sample of healthy children consisted of 259 to 718 (depending on the
questionnaire) participants who were assessed in either physicians’ offices during checkups or by telephone. Compared to parents with similar-aged healthy children, parents of
children with SMA reported significantly lower scores in all domains of the PedsQL 4.0
Generic Core module (P < 0.001), and all domains of the PedsQL 3.0 Fatigue module,
including the PedsQL 3.0 Total fatigue module (P < 0.001), PedsQL 3.0 Fatigue general
summary score (P < 0.001), PedsQL 3.0 Fatigue sleep/rest summary score (P < 0.001),
and the PedsQL 3.0 Fatigue cognitive fatigue summary score (P = 0.042). (Table 4-5).
(59, 60, 63) Un-paired t-tests were also conducted to assess the differences between the
parent proxy scores from similar-aged children with DMD and children with SMA. The
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parent proxy sample of children with DMD consisted of 69 to 96 (depending on the
questionnaire) participants who were also recruited from the CNDR. Parents of children
with DMD reported significantly higher scores in the PedsQL 3.0 NM total score, “About
My NM Disease” (P < 0.001) and “About Our Family Resources” (P < 0.001) summary
scores. This is in comparison to parents of children with SMA who reported significantly
higher PedsQL 4.0 Generic emotional summary score (P = 0.008), Generic social
summary score (P = 0.026), Generic psychosocial summary score (P = 0.008), and
PedsQL 3.0 Fatigue cognitive summary score (P = 0.001) compared to the parents of
children with DMD (Table 4-5).

Objective 2 Results: To examine the agreement between
child reported and parent/caregiver proxy scores in
children with SMA
Paired t-tests were conducted to compare parent proxy and child reported (≥ 5 years)
PedsQL scores for the PedsQL 4.0 Generic Core module, PedsQL 3.0 Fatigue module,
and PedsQL 3.0 NM module (Table 4-6). The parent proxy consistently rated the
PedsQL scores lower compared to the child report for most of the PedsQL 4.0 Generic
and PedsQL 3.0 NM modules, however not all results were statistically significant. The
parent proxy-reported scores were significantly lower for the PedsQL 3.0 NM total
module (P = < 0.001), “about my neuromuscular disorder” summary score (P = 0.001),
and “about our family resources” summary score (P < 0.001). For the PedsQL 4.0 Fatigue
module, the parent proxy scores were significantly lower for the “general fatigue”
summary score (P = 0.03) and significantly higher for the “cognitive fatigue” (P = 0.01)
summary score (Table 4-6).
The ICC between the parent proxy and child reported (≥ 5 years) PedsQL scores for the
PedsQL 4.0 Generic Core module, PedsQL 3.0 Fatigue module, and the PedsQL 3.0 NM
module were calculated using a two-way random model (2,1).(71) The ICCs were
compared to the guidelines established by Koo 2016 et al. to determine whether the
correlations were considered: “poor”, “moderate”, “good”, or “excellent”. (72) The
guidelines state that when the reliability coefficient is below 0.50, this is indicative of
“poor” reliability. When it is between 0.50 and 0.75 the reliability is “moderate”, between
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0.75 and 0.90 the reliability is “good”, and when it is above 0.90 the reliability is
considered “excellent” (Table 4-7).

PedsQL: Generic Core Module
The ICC between the child self-report and parent proxy scores were considered “poor”
for the physical, social, and school summary scores. The ICC was reported as “moderate”
for the generic core total score, psychosocial summary score and emotional summary
score. (Table 4-7).

PedsQL: Fatigue Module
The ICC between the child self-report and parent proxy scores were considered “good”
for the total fatigue module score and cognitive fatigue summary score. The ICC was
considered “moderate” for both the general fatigue and sleep/rest fatigue summary scores
(Table 4-7).

PedsQL: Neuromuscular Module
The ICC between the child self-report and parent proxy scores were considered
“moderate” for the about my neuromuscular disease summary score. The ICC was
considered “poor” for the total NM score, communication summary score, and family
resources summary score (Table 4-7).

Objective 3 Results: To explore associations between both
the child reported and parent/caregiver proxy HRQL
scores to clinical and family characteristics in children with
SMA
Bivariate Analysis
This section reports on the associations between both the clinical and family
characteristics collected in the questionnaires, to the child self-reported and
parent/caregiver proxy HRQL scores. The following clinical and family characteristics
were collected and assessed through bivariate analysis: age, SMA type, ambulatory
status, ventilation support, scoliosis, approved medications, not approved medications,
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parental work status, parental educational status, parental marital status, and total yearly
household income.
Age
Age was assessed as both a continuous and a categorical variable. Age was not found
significantly associated with any child or parent/caregiver proxy PedsQL score when
assessed either as a continuous or categorical variable.
SMA Type
SMA type was assessed as a categorical variable (type 1, type 2, type 3, and type 4) and
was significantly associated with the child reported PedsQL 4.0 Generic physical
summary score (χ2 = 6.70; P = 0.08). SMA type was also significantly associated with the
parent/caregiver reported (χ2 = 7.52; P = 0.06) PedsQL 3.0 NM total score.
Ambulatory Status
Ambulatory status was significantly associated with PedsQL 4.0 Generic physical
summary score for the child report (Z = 2.68; P = 0.01). Ambulatory status was also
significantly associated with the PedsQL 3.0 NM total score for the parent/caregiver
proxy-report (Z = 2.34; P = 0.02).
Ventilation Support
Ventilation support was assessed as a categorical variable (none, Bi-PAP, tracheostomy,
other). It was significantly associated with parent/caregiver proxy PedsQL 3.0 NM total
score (χ2 = 10.60; P = 0.005).
Scoliosis
Scoliosis was not considered significantly associated with any child or parent/caregiver
reported PedsQL 4.0 Generic total score, PedsQL 4.0 Generic sub-scores, or the PedsQL
3.0 NM module total score.

49

Approved Medications
Approved medications were not considered significantly associated with any child
reported PedsQL 4.0 Generic total score, PedsQL 4.0 Generic sub-scores, or the PedsQL
3.0 NM total score. However, it was significantly associated with the parent/caregiver
proxy-reported PedsQL 3.0 NM total score (Z = -2.02, P = 0.05).
Non-Approved Medications
Non-approved medications were not significantly associated with any child or
parent/caregiver reported PedsQL 4.0 Generic total score, PedsQL 4.0 Generic subscores, or the PedsQL 3.0 NM total score.
PedsQL Fatigue Module
The PedsQL 3.0 Fatigue module score was significantly associated with all the child and
parent/caregiver reported PedsQL 4.0 Generic total score (child [0.65, P < 0.001]; parent
[0.51, P < 0.001]), Generic 4.0 psychosocial summary score (child [0.75, P < 0.001];
parent [0.66, P < 0.001]), and the PedsQL 3.0 NM module total score (child [0.61, P <
0.001]; parent [ 0.49, P < 0.001]).
Parental Education
Parental education was assessed as a categorical variable (high school or less, vocational,
college or university). Education was not significantly associated to any of the child or
parent/caregiver reported PedsQL scores.
Parental Work Status
Parental work status was assessed as a categorical variable (not working due to my
child’s health, not working for “other” reasons, working full-time, working part-time,
stay-at-home parent, student, retired). Parental work status was not significantly
associated any of the child reported or parent/caregiver proxy PedsQL scores.
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Parental Marital Status
Parental marital status was assessed as a categorical variable (married, living common
law, widowed, separated, divorced, single). Parental marital status was not significantly
associated caregiver proxy PedsQL scores.
Total Household Income
Total household income was assessed as a categorical variable (>$20,000, $20,000$39,999, $40,000-$59,999$60,000-$79,999, $80,000-$99,999, $100,000 or more,
undisclosed). Total household income was not significantly associated with any of the
parent/caregiver reported PedsQL scores.
Summary
Due to the small sample size and exploratory nature of this objective, the correlates
included in the regression model were determined based on a combination of a literature
review (Table 4-8), clinical expertise (Section 3.8), and bivariate analyses. The
following covariates were included in the regression model predicting the child selfreported and parent proxy-reported scores: PedsQL 3.0 Fatigue score (continuous),
ventilation (categorical), ambulation (binary), and SMA type (categorical) (Table 4-9).
Each of these covariates was assessed as significantly associated to the child reported and
parent/caregiver proxy HRQL scores based on the bivariate analysis and either the
literature review or clinical expertise.
As previously shown above in the results section, all the variables (fatigue score,
ventilation status, and ambulatory status) the clinicians selected were significantly
associated (P < 0.10) to at least one of the PedsQL 4.0 Generic total score, PedsQL 4.0
Generic Core physical summary score, PedsQL 4.0 Generic Core psychosocial summary
socre, or PedsQL 3.0 NM total score in the bivariate analysis.
The assumptions of a linear regression of linearity and normality were met and the test
for collinearity was not significant for the multivariable regression models.
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Regression Analysis
Multivariable linear regressions were performed on HRQL outcomes in both child selfreport and parent proxy-reports. The HRQL outcomes include the PedsQL 4.0 Generic
Core total score, PedsQL 4.0 Generic physical summary score, PedsQL 4.0 Generic
psychosocial summary score, and PedsQL 3.0 NM module total score.
Parent report
PedsQL 4.0 Generic Core Total
Fatigue and SMA type were significantly associated with the PedsQL 4.0 Generic Core
total score, with an R2 of 0.48. On average, a one unit increase in the fatigue score was
associated with a 0.34 increase in the PedsQL 4.0 Generic module score (P = 0.005).
Therefore, a better fatigue score (less fatigue) is associated with a better Generic module
score (higher HRQL) (Table 4-10).
PedsQL 4.0 Generic Core Physical Summary Score
None of the variables was significantly associated with the PedsQL 4.0 Generic Core
physical summary score (Table 4-10), with an R2 of 0.22.
PedsQL 4.0 Generic Core Psychosocial Summary Score
Fatigue and SMA type were significantly associated with the PedsQL 4.0 Generic Core
psychosocial summary score. On average, a one unit increase in the fatigue score was
associated with a 0.50 increase in the PedsQL 4.0 Generic psychosocial module score (P
< 0.0001). Therefore, a better fatigue score is associated with a better psychosocial score.
The R2 for this model was 0.56 (Table 4-10).
PedsQL 3.0 Neuromuscular Total
Fatigue and ventilation are both significantly associated with PedsQL 3.0 NM total score.
On average, a one unit increase in the fatigue score was associated with a 0.56 increase in
the PedsQL 3.0 NM total score (P = 0.0001). Therefore, a better fatigue score is
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associated with a better neuromuscular score. Those on non-invasive Bi-PAP ventilation
have on average a 11.03 lower PedsQL 3.0 NM score, compared to those not on any
ventilation (P = 0.03) (Table 4-10). The R2 for this model was 0.59.
Child report
PedsQL 4.0 Generic Core Total
Fatigue and SMA type are significantly associated with the PedsQL 4.0 Generic Core
total score. On average, a one unit increase in the fatigue score was associated with a 0.46
increase in the PedsQL 4.0 Generic module score (P = 0.0004), therefore a better fatigue
score (less fatigue) is associated with a better generic score (better HRQL). (Table 4-11).
The R2 for this model was 0.67.
PedsQL 4.0 Generic Core Physical Summary Score
Ambulation and SMA type were significantly associated with the PedsQL 4.0 Generic
Core psychical summary score. On average, ambulatory patients have a PedsQL 4.0
Generic Core physical summary score of 25.62 higher than non-ambulatory patients (P =
0.02), (Table 4-11). The R2 for this model was 0.67.
PedsQL 4.0 Generic Core Psychosocial Summary Score
Only fatigue was significantly associated with the PedsQL 4.0 Generic Core psychosocial
summary score. On average, a one unit increase in the fatigue score was associated with a
0.71 increase in the PedsQL 4.0 Generic psychosocial summary score (P < 0.0001)
(Table 4-11). Therefore, a better fatigue score is associated to a better psychosocial
score. The R2 for this model was 0.63.
PedsQL 3.0 Neuromuscular Total
Fatigue and ventilation were significantly associated with the PedsQL 3.0 NM total score.
On average, a one unit increase in the fatigue score was associated with a 0.56 increase in
the PedsQL 3.0 NM total score (P = 0.0007), therefore a better fatigue score is associated
with a better NM score. Additionally, those with a tracheostomy have on average a 36.54
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lower PedsQL 3.0 NM score, compared to those not on any ventilation (P = 0.01) (Table
4-11). The R2 for this model was 0.60.
Regression results summary
The factor most consistently associated with HRQL outcomes was fatigue for both the
child self-report and parent proxy-report. Fatigue was significantly associated with the
PedsQL 4.0 Generic Core total score and psychosocial summary score, and the PedsQL
3.0 NM module total score.
SMA type was associated with the PedsQL 4.0 Generic total and physical summary
scores for child reported HRQL scores, and SMA type was associated with the PedsQL
4.0 Generic total and psychosocial summary scores for parent reported scores.
Ventilation was significantly associated with the PedsQL 3.0 NM total score for both
parent/caregiver proxy and child self-reports. Lastly, ambulation was significantly
associated with the child self-reported PedsQL 4.0 Generic physical summary score.
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Table 4-1 Respondent vs. Non-respondent Demographic and Clinical Characteristics of
Child with SMA
Variables

Responders
(N = 45)
N (%)
9.9 (4.8)

Non-responders
(N = 32)
N (%)
11.6 (4.9)

Significance
(P value)

10 (22.2)
27 (60.0)
7 (15.6)
1 (2.2)

10 (31.3)
16 (50.0)
6 (18.8)
0 (0.0)

P=0.70
(Fischer’s exact
test)

Ambulant (%)

8 (17.8)

8 (25.0)

Nusinersen (approved
medication) use (%)
Ventilation use (%)
None

22 (48.9)

16 (50.0)

P = 0.57
(chi-square)
P= 0.18
(chi-square)

22 (48.9)
3 (6.7)
20 (44.4)

14 (43.8)
3 (9.4)
15 (46.9)

P= 0.83
(Fisher’s exact
test)

73.67 (33.4)

61.76 (32.9)

P = 0.13

Age (years, SD)
SMA type (%)
Type 1
Type 2
Type 3
Type 4

Tracheostomy
Non-invasive Bi-PAP
FVC at last exam (%, SD)

P = 0.14
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Table 4-2 Characteristics of Respondent Families
Variables
Age of parent respondents (years, SD)
Female parent
Biological parent
Married
Living with Spouse
Parents highest level of education
Less than secondary school
Secondary school diploma or equivalent
Some postsecondary education
Apprenticeship or trade's certificate or diploma
College, CEGEP or other non-university certificate
or diploma
Bachelor’s Degree
Master’s Degree
Professional Degree
Not reported/Missing
Parent’s work status
Full-time
Part-time
Stay-at home parent
Not working due to my child's health
Not working for other reasons
Household income
$20,000-$29,000
$30,000-$39,000
$40,000-$49,000
$50,000-$59,000
$60,000-$69,000
$70,000-$79,000
$80,000-$89,000
$90,000-$99,000
$100,000-$149,000
≥$150,000
Prefer not to disclose
Not reported/Missing

Responders (N = 45)
N (%)
40.8 (10.1)
34 (75.6)
42 (93.3)
40 (88.9)
43 (95.6)
1 (2.2)
4 (8.9)
1 (2.2)
3 (6.7)
8 (17.8)
17 (37.8)
4 (8.8)
6 (13.3)
1 (2.2)

23 (51.1)
9 (0.2)
3 (6.7)
7 (15.6)
3 (6.7)
2 (4.4)
4 (8.9)
1 (2.2)
1 (2.2)
3 (6.7)
1 (2.2)
5 (11.1)
1 (2.2)
5 (11.1)
16 (35.6)
5 (11.1)
1 (2.2)
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Table 4-3 PedsQL Scores of Children vs. Parent-Proxy
Module

Parent (N)

Parent Scores
(All Ages)
Mean (SD)
Median
[Range]

Child (N)

Child Scores
Mean (SD)
Median
[Range]

54.48 (13.85)
52.17
[27.78-100]
34.48 (26.50)
25.00
[0.00-100]
64.67 (13.03)
65.00
[45-100]
71.16 (18.09)
70.00
[35-100]
57.98 (17.43)
57.50
[30-100]
61.41 (19.70)
60.00
[15-100]

33

57.35 (13.83)
56.52
[35.71-100]
31.63 (18.47)
26.56
[6.25-100]
70.41 (15.66)
71.67
[40-100]
74.85 (18.31)
70.00
[40-100]
66.52 (17.57)
60.00
[30-100]
68.33 (18.10)
70.00
[30-100]

54.19 (17.70)
53.00
[17-100]
54.51 (19.76)
55.88
[13.24-100]

33

61.05 (27.68)
66.67
[0-100]
48.95 (22.77)
50.00
[0-100]

28

75.50 (15.45)
73.61
[33.33-100.00]
67.42 (20.75)
66.67

33

PedsQL 4.0 Generic Core Module
Total Score

42

Physical Health
Summary Score

39

Psychosocial Health
Summary Score

42

Emotional Summary
Score

43

Social Summary
Score

42

School Summary
Score

39

32

33

33

33

33

PedsQL 4.0 Neuromuscular Module
Total Score

43

About my
Neuromuscular
Disease

43

Communication

43

About our Family
Resources

43

33

28

65.77 (16.04)
67.00
[31.25-100]
63.38 (17.91)
66.18
[27.94-100]
72.32 (24.43)
75.00
[0-100]
73.57 (20.68)
77.50
[35-100]

PedsQL 4.0 Fatigue Module
Total Score

44

General Fatigue

44

33

74.86 (15.12)
72.22
[44.44-100]
74.74 (17.50)
75.00
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[12.5-100]
Sleep/Rest Fatigue

44

Cognitive Fatigue

44

[33.33-100]

76.33 (14.92)
75.00
[33.33-100]
82.77 (17.87)
89.58
[50.00-100]

33

48.84 (18.35)
46.53
[4.17-86.81]
49.66 (20.88)
48.75
[1.25-96.25]
48.96 (23.10)
53.13
[3.13-100]
49.07 (22.52)
50.00
[4.17-100]

-

-

-

-

-

-

-

-

48.31 (25.81)
45.00
[0-100]
43.33 (24.66)
43.75
[0-100]
56.78 (25.41)
55.00
[0-100]
50.93 (23.98)
50.00
[8.33-100]
44.11 (21.93)
50.00
[0-95]
32.96 (25.87)
33.33
[0-100]
58.56 (25.01)
60.00
[0-100]

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

73.23 (16.86)
75.00
[37.5-100]
76.26 (21.76)
75.00
[20.83-100]

PedsQL 2.0 Family Impact Module
Total Score

45

Parent HRQL
Summary Score

45

Family functioning
Summary Score

45

Physical score

45

Emotional Score

45

Social Score

45

Cognitive Score

45

Communication
Score

45

Worry Score

45

Daily Score

45

Family Relationships
Score

45
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Table 4-4 Mean self-reported PedsQL score in children with SMA, children with DMD, and healthy children
N

SMA
Mean (SD)
(Current study
sample)

N

DMD
(Wei et al 2016,
El-Aloul et al
2019)(59, 60)
Mean (SD)

N

Healthy
(Varni et al
2001)(63)
Mean (SD)

SMA and Healthy
Comparison

SMA and DMD
comparison
Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
-0.95 (-7.10, 5.20)
[3.14]
P = 0.76
-13.67 (-22.84, -4.50)
[4.68]
P = 0.004
5.01 (-1.26, 11.28)
[3.20]
P = 0.12
8.45 (0.12, 16.78)
[4.25]
P = 0.05
3.22 (-4.08, 10.52)
[3.72]
P = 0.39
1.63 (-6.08, 9.34)
[3.93]
P = 0.68
-6.23 (-11.98, -0.48)
[2.93]
P = 0.04
-8.32 (-15.13, -1.51)
[3.12]
P = 0.009

Social

33

66.52 (17.57)
[30-100]

83

63.3 (18.3)

399

87.4 (17.2)

School

33

68.33 (18.10)
[30-100]

81

66.7 (19.4)

386

78.6 (20.5)

Neuromuscular 33
Module Total
Score
About my
33
neuromuscular
disease

65.77 (16.04)
67.00
[31.25-100]
63.38 (17.91)
66.18
[27.94-100]

83

72.0 (13.5)

-

NA

Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
-25.65 (-30.95, -20.35)
[2.71]
P < 0.001
-52.77 (-59.03, -46.51)
[3.19]
P < 0.001
-11.99 (-17.50, -6.48)
[2.81]
P < 0.001
-6.05 (-12.98, 0.88)
[3.53]
P = 0.09
-20.88 (-27.00, -14.76)
[3.12]
P < 0.001
-10.27 (-17.50, -3.05)
[3.69]
P = 0.006
-

82

71.7 (13.9)

-

NA

-

Generic Core
Total Score

32

57.35 (13.83)
[35.71-100]

82

58.3 (15.5)

401

83.0 (14.8)

Physical
summary

32

31.63 (18.47)
[6.25-100]

82

45.3 (23.8)

400

84.4 (17.3)

Psychosocial
summary

33

70.41 (15.66)
[40-100]

83

65.4 (15.5)

399

82.4 (15.5)

74.85 (18.31)
[40-100]

83

66.4 (21.5)

400

80.9 (19.6)

Emotional

33
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Communication

28

72.32 (24.43)
75.00
[0-100]
73.57 (20.68)
77.50
[35-100]
74.86 (15.12)
[44.44-100]

64

63.9 (26.4)

-

NA

-

64

74.9 (20.1)

-

NA

-

66

71.6 (15.2)

209

81.8 (12.5)

-6.94 (-11.67, -2.21)
[2.41]
P = 0.004
-11.36 (-17.61, -5.11)
[3.19]
P = 0.001
-3.57 (-9.58, 2.44)
[3.07]
P = 0.25
-6.14 (-13.89, 1.61)
[3.96]
P = 0.13

About our
family resources

28

Fatigue
Module Total
Score
General Fatigue

33

33

74.74 (17.50)
[33.33-100]

66

70.2 (19.7)

209

86.1 (13.6)

Sleep/Rest
Fatigue

33

73.23 (16.86)
[37.5-100]

66

74.0 (17.5)

209

76.8 (16.3)

Cognitive
Fatigue

33

76.26 (21.76)
[20.83-100]

65

70.9 (23.0)

209

82.4 (16.5)

8.42 (-3.05, 19.90)
[5.85]
P = 0.15
-1.33 (-10.33, 7.67)
[4.59]
P = 0.77
3.26 (-3.08, 9.60)
[3.24]
P = 0.32
4.54 (-3.40, 12.48)
[4.05]
P = 0.27
-0.77 (-8.00, 6.46)
[3.69]
P = 0.84
5.36 (-4.11, 14.83)
[4.83]
P = 0.27

Note: NA = Not applicable because the NM module is a disease specific HRQL measure, thus would not be applied to healthy
controls
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Table 4-5 Mean parent reported PedsQL score in children with SMA, children with DMD, and healthy children
N

Generic Core
Total Score

42

Physical
summary

39

Psychosocial
summary

42

Emotional

43

Social

42

School

39

Neuromuscular
Module Total
Score
About my
neuromuscular
disease
Communication

43

43

43

SMA
Mean (SD)

54.48 (13.85)
52.17
[27.78-100]
34.48 (26.50)
25.00
[0.00-100]
64.67 (13.03)
65.00
[45-100]
71.16 (18.09)
70.00
[35-100]
57.98 (17.43)
57.50
[30-100]
61.41 (19.70)
60.00
[15-100]
54.19 (17.70)
53.00
[17-100]
54.51 (19.76)
55.88
[13.24-100]
61.05 (27.68)

N

DMD
(Wei et al 2016,
El-Aloul et al
2019)(59, 60)
Mean (SD)

N

Healthy
(Varni et al
2001)(63)
Mean (SD)

SMA and Healthy
Comparison

SMA and DMD
comparison

NA

Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
-33.12 (-36.98, -29.27)
[1.97]
P < 0.001
-54.82 (-63.32, -46.42)
[4.29]
P < 0.001
-22.13 (-26.12, -18.14)
[2.03]
P < 0.001
-11.44 (-16.84, -6.05)
[2.75]
P < 0.001
-33.62 (-38.99, -28.25)
[2.74]
P < 0.001
-24.09 (-29.83, -18.35)
[2.93]
P < 0.001
-

-

NA

-

-

NA

-

Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
2.58 (-3.14, 8.30)
[2.92]
P = 0.38
-8.32 (-17.99, 1.35)
[4.93]
P = 0.09
7.47 (2.04, 12.90)
[2.77]
P = 0.008
8.96 (2.47, 15.45)
[3.31]
P = 0.008
7.98 (1.04, 14.91)
[3.54]
P = 0.026
2.71 (-4.58, 10.00)
[3.72]
P = 0.47
-13.11 (-19.30, -6.92)
[3.16]
P < 0.001
-14.69 (-21.20, -8.18)
[3.32]
P < 0.001
3.05 (-7.14, 13.24)

95

51.9 (16.5)

717

87.6 (12.3)

95

42.8 (25.7)

717

89.3 (16.4)

95

57.2 (15.7)

717

86.6 (12.8)

95

62.2 (18.0)

718

82.6 (17.5)

95

50.0 (20.0)

716

91.6 (14.2)

95

58.7 (19.5)

611

85.5 (17.6)

96

67.3 (17.0)

-

96

69.2 (17.3)

96

58.0 (28.6)
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About our
family resources

43

Fatigue
Module Total
Score
General Fatigue

44

Sleep/Rest
Fatigue

44

Cognitive
Fatigue

44

44

66.67
[0-100]
48.95 (22.77)
50.00
[0-100]
75.50 (15.45)
73.61
[33.33-100.00]
67.42 (20.75)
66.67
[12.5-100]
76.33 (14.92)
75.00
[33.33-100]
82.77 (17.87)
89.58
[50.00-100]

96

66.7 (23.9)

-

NA

-

69

70.8 (16.0)

259

88.2 (11.1)

69

64.2 (20.1)

259

88.8 (12.3)

69

76.9 (18.0)

259

87.6 (13.5)

-12.70 (-17.46, -7.94)
[2.43]
P < 0.001
-21.38 (-27.69, -15.07)
[3.22]
P < 0.001
-11.27 (-15.65, -6.89)
[2.24]
P < 0.001

[5.20]
P= 0.56
-17.75 (-26.22, -9.28)
[4.32]
P < 0.001
4.70 (-1.27, 10.67)
[3.05]
P = 0.13
3.22 (-4.48, 10.92)
[3.93]
P = 0.41
-0.57 (-6.95, 5.81)
[3.26]
P = 0.86

69

69.7 (24.6)

259

88.2 (16.0)

-5.43 (-10.63, -0.23)
[2.66]
P= 0.042

13.07 (5.22, 20.92)
[4.00]
P = 0.001

Note: NA = Not applicable because the NM module is a disease specific HRQL measure, thus would not be applied to healthy
controls
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Table 4-6 Parent and Child Paired Samples Statistics
Module

Parent
(N)

Parent Scores
Mean (SD)

Child
(N)

Child Scores
Mean (SD)

Mean Difference (95%CI)
[SD]

P-value
(2-sided)

PedsQL 4.0 Generic Core Module
Total Score

31

55.98 (13.99)

31

57.62 (13.50)

-1.64 (-6.53, 3.25)
[13.33]

0.50

Physical Health
Summary Score
Psychosocial
Health Summary
Score
Emotional
Summary Score

28

36.64 (29.90)

28

32.46 (19.19)

0.50

31

65.99 (13.85)

31

70.92 (14.94)

4.18 (-8.21, 16.57)
[31.95]
-4.93 (-10.00, 0.14)
[-10.01]

31

70.65 (19.78)

31

74.52 (18.14)

-3.87 (-9.51, 1.77)
[15.37]

0.17

Social Summary
31
60.00 (17.70)
Score
School Summary
31
65.81 (17.03)
Score
PedsQL 4.0 Neuromuscular Module

31

67.42 (16.78)

0.05

31

69.19 (17.18)

-7.42 (-14.96, 0.13)
[20.57]
-3.34 (-9.99, 3.22)
[18.00]

Total Score

31

53.94 (18.99)

31

65.76 (15.57)

<0.001

About my
Neuromuscular
Disease
Communication

31

53.13 (21.16)

31

63.39 (17.83)

-11.82 (-17.56, -6.10)
[15.59]
-10.26 (-15.90, -4.61)
[15.38]

27

65.12 (26.25)

27

71.30 (24.28)

0.24

About our Family
Resources

27

50.74 (23.64)

27

72.59 (20.40)

-6.17 (-16.74, 439)
[26.71]
-21.85 (-31.31, -12.40)
[23.91]

0.06

0.30

0.001

<0.001
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PedsQL 4.0 Fatigue Module
Total Score

32

75.95 (15.92)

32

75.03 (15.33)

General Fatigue

32

67.84 (20.64)

32

75.00 (17.68)

Sleep/Rest Fatigue

32

76.95 (15.19)

32

72.92 (17.03)

Cognitive Fatigue

32

83.07 (18.78)

32

76.82 (21.87)

0.93 (-2.92, 4.78)
[10.67]
-7.16 (-13.61, -0.72)
[17.87]

0.63

4.04 (-1.13, 9.21)
[14.34]
6.25 (1.35, 11.51)
[13.59]

0.12

0.03

0.01
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Table 4-7 Agreement between parent and child report of child’s health-related quality of life
Scale

Subscale

N (ParentChild
Pairs)
31

0.53 (0.23, 0.75)

Moderate

Physical summary
Psychosocial summary
Emotional
Social
School

28
31
31
31
31
31

0.19 (-0.19, 0.53)
0.52 (0.21, 0.73)
0.67 (0.42, 0.82)
0.27 (-0.06, 0.56)
0.47 (0.15,0.71)
0.49 (0.07, 0.13)

Poor
Moderate
Moderate
Poor
Poor
Poor

About my neuromuscular
disease
Communication
About our family
resources

31

0.61 (0.23, 0.81)

Moderate

27
27

0.44 (0.9, 0.70)
0.28 (-0.08, 0.59)

Poor
Poor

32

0.77 (0.58, 0.88)

Good

32
32
32

0.54 (0.24, 0.74)
0.59 (0.32, 0.78)
0.75 (0.51, 0.87)

Moderate
Moderate
Good

Generic Core Total
Score

Neuromuscular Module
Total Score

Fatigue Module Total
Score
General Fatigue
Sleep/Rest Fatigue
Cognitive Fatigue

ICC (95% CI)

Rating
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Table 4-8 Variables Included in Regression: Literature References
Covariate
1

Fatigue

3

Functional
Measures/Ambulatory
status

4

SMA Type

5

Ventilation Support

Literature references
(32) Belter et al found that all PROMIS fatigue scores in the SMA
population were worse than the general population. However, there
didn’t appear to be a trend of scores increasing or decreasing by
SMA type or functional status
(50)Montes et al assessed the comparison between the fatigue score
to the PedsQL score and noted participants and their parents
reported good quality of life overall (83, 86.5 – on a scale of 0–100),
while children reported slightly lower levels of fatigue than their
parents (85,74 – on a scale of 0–100)
(35)Dunaway et al found that perceived fatigue was not associated
with function, quality of life, or
fatigability in ambulatory SMA patients. Neither age, type, nor
ambulatory status influenced perceived fatigue
(41) Vega et al showed the group with less motor disability showed
slightly better overall HRQL scores, only in the communication
domain
(34, 36) De Oliveria and Frongia found no association between
functional status and HRQL
(35) Dunaway compared PedsQL and short form scores with fatigue
and function scores, which showed the Peds QL NM child and
parent report didn't correlate to the function tests (Hammersmith or
six-minute walk test) (all correlations had alpha levels of p > 0.05).
They also found no association between ambulatory status and
perceived fatigue
(51)Swoboda et al found that the QOL didn't improve as the
MHFMS improved, but there was evidence of deterioration in QOL
as the hammersmith score declined
(43)Weaver et al showed significant differences in PedsQL family
impact module were found in Weaver et al between SMA type I and
type II
(36) Frongia reported only 4 out of 42 parents of children with SMA
2 and 3 out of 9 parents of SMA type 3 children reported scores >80
in PedsQL
(37)Klug reported children with SMA III assessed their diseasespecific HRQL as fairly high (self-reported), while SMA I children
had a low proxy-assessed HRQL (69 vs. 34 on a scale with 0 = min.
and 100 = max.; p < 0.001)
(42)Wagner reported all child and parents reported PedsQL 4.0
Generic Core Scales and PedsQL 3.0 Neuromuscular Module scores
decreased in all three types of SMA patients, with the most
decreased scores seen in type 1 SMA patients
(34, 41)De Oliviera and Vega both found no differences in QoL
scores when comparing different types of SMA
(43) Weaver et al showed that ventilation support impacted proxy
quality of life perspectives
(32)Among caregivers, the greatest levels of activity
were experienced among those caring for affected individuals on
permanent ventilation, 83.1%).
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Table 4-9 Clinical and Demographic Factors Included in the Regression Model
Predicting Child and Parent Reported Scores
Clinical Factors
• SMA type (Type 1,2,3 and 4)
• Ambulatory status (yes/no)
• Fatigue (PedsQL 4.0 Fatigue module)
•

Assisted ventilation
(None, Tracheostomy/Ventilation, Non-invasive
Bi-PAP, Other)

Sources of support
Bivariate analysis, literature review
Clinician opinion, bivariate analysis
Clinician opinion, bivariate analysis, literature
review
Clinician opinion, bivariate analysis, literature
review
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Table 4-10 Multivariable Linear Regression Analyses to Predict Parent Proxy-Reported HRQL

Fatigue
Ventilation
Ventilation Tracheostomy
Ventilation Bi-PAP
Ventilation None (ref)
Ambulation
Ambulatory
Non-Ambulatory (ref)
SMA Type
SMA Type 1
SMA Type 2 (ref)
SMA Type 3
SMA Type 4

PedsQL 4.0 Generic
Core Total
(N = 42)
0.35 (0.01)

Dependent Variables
B (P-Value)
PedsQL 4.0 Generic
Core Physical
(N = 39)
-0.03 (0.92)

PedsQL 4.0 Generic
Core Psychosocial
(N =42)
0.50 (< 0.001)

PedsQL 3.0 Neuromuscular
Total
(N = 43)
0.56 (<0.001)

10.99 (0.22)
-0.82 (0.85)
-

11.19 (0.64)
-7.67 (0.47)
-

-0.03 (0.99)
0.27 (0.94)
-

-6.20 (0.53)
-11.03 (0.03)
-

-2.75 (0.76)
-

-0.99 (0.96)
-

-5.70 (0.47)
-

8.92 (0.37)
-

-8.40 (0.13)
2.76 (0.75)
39.18 (0.01)

-9.88 (0.46)
-0.91 (0.97)
63.92 (0.08)

-5.03 (0.30)
6.22 (0.42)
28.33 (0.03)

-8.04 (0.18)
0.94 (0.92)
17.99 (0.28)
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Table 4-11 Multivariable Linear Regression Analyses to Predict Child Self-Reported HRQL

Fatigue
Ventilation
Ventilation Tracheostomy
Ventilation Bi-PAP
Ventilation None (ref)
Ambulation
Ambulatory
Non-Ambulatory (ref)
SMA Type
SMA Type 1
SMA Type 2 (ref)
SMA Type 3
SMA Type 4

PedsQL 4.0 Generic
Core Total (N= 33)
0.46 (0.0004)

Dependent Variables
B (P-Value)
PedsQL 4.0 Generic
PedsQL 4.0 Generic Core
Core Physical (N = 32)
Psychosocial (N =33)
0.22 (0.16)
0.71 (<0.0001)

PedsQL 3.0 Neuromuscular
Total (N = 33)
0.56 (0.0007)

-16.94 (0.13)
6.09 (0.12)
-

2.96 (0.55)
-

-18.52 (0.16)
1.45 (0.75)
-

-36.54 (0.01)
-2.44 (0.62)
-

4.70 (0.54)
-

25.62 (0.02)
-

-4.36 (0.63)
-

5.05 (0.61)
-

3.66 (-0.50)
1.84 (0.81)
31.47 (0.02)

8.75 (0.22)
-7.68 (0.44)
44.90 (0.01)

3.08 (0.63)
-1.01 (0.91)
16.33 (0.29)

6.52 (0.35)
3.84 (0.69)
15.70 (0.34)
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Chapter 5
5.0 Discussion
This chapter provides interpretations of the study findings and discusses them within the
context of existing literature. The strengths and limitations of the study are also be
discussed, in addition to the implications of the findings and the future directions.

Objective 1: To describe the HRQL in children with SMA from the
patients’ and parents’ perspective
The first objective was to describe the HRQL in children with SMA from the patients’
and parents’ perspectives. The results show that, from both the child and parent
perspectives, HRQL is lowest in the physical domains and highest in the fatigue domains.
As a reference, HRQL of children with SMA and the parent/caregiver proxy scores of
children with SMA were compared to those of similar-aged healthy children and similaraged children with another chronic NM disease (Duchenne Muscular Dystrophy) using
published data. The results from this analysis showed that, compared to healthy children,
children with SMA reported lower HRQL, with the largest difference being in the
physical domains (which includes items such as walking, running, taking a bath etc.).
Compared to children with DMD, children with SMA reported similar levels for overall
HRQL, the neuromuscular domain, and fatigue. The largest differences were found in the
physical and neuromuscular summaries, where children with SMA reported significantly
lower levels. Despite also being a severe progressive NM disorder, children with DMD
have greater independent mobility until more advanced stages of their disease which may
explain this discrepancy. Parents of children with DMD reported significantly better
HRQL in the neuromuscular domain, “About My NM Disease” and “About Our Family
Resources” summary scores. This is in comparison to parents of children with SMA who
reported significantly better emotional, social, psychosocial, and fatigue scores compared
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to the parents of children with DMD. Given that DMD has a much higher burden of
cognitive and mental health problems, this finding was expected.(73) It is important to
note that although SMA and DMD are both common degenerative neuromuscular
diseases found in children, there are some differences between them. First, DMD is an xlinked disease, thus it only occurs in males whereas SMA is in both males and females.
Additionally, although those with DMD may have greater independent mobility early in
their disease, the progression is quite rapid and males with DMD are unable to walk by
the age of 12.
Our results are comparable to those of another study that also assessed the HRQL in
children with SMA and their parent proxy with a much larger sample size (Iannaccone et
al. 2009).(49) The Iannaccone et al 2009 study assessed the feasibility, reliability, and
validity of the PedsQL Generic core module and the PedsQL NM module, in 176
similar-age children with SMA and their parents. For the child reported HRQL scores,
the HRQL PedsQL scores were similar for the PedsQL Generic and PedsQL NM total
and sub scores except for the PedsQL Generic physical summary score, where our score
was substantially lower compared to the data published by Iannaccone et al. 2009 (Table
5-1).
For the parent proxy-report, the majority of the HRQL PedsQL scores were similar
except for the psychosocial, emotional, and family resources score PedsQL Generic
psychosocial summary score, the PedsQL Generic emotional summary score, and the
PedsQL NM family resources summary score. The psychosocial and family resources
scores were significantly lower in this study compared to Iannaccone, and the emotional
summary score in this study was substantially higher compared to Iannaccone et al. 2009
(Table 5-2).
It was hard to assess the reasons for the difference in scores between our study and
Iannaccone et al. 2009, since Iannaccone et al. 2009 did not describe the demographic
and clinical characteristics of their sample. It may be because our sample size was much
smaller than their sample size, thus our sample size may not have been as representative
of the general SMA population.
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Objective 2: To examine the agreement between child reported and
parent/caregiver proxy scores in children with SMA
The second objective was to assess the agreement between the child reported (≥ 5 years)
and parent/caregiver proxy scores. Both paired t-tests and ICC analyses were performed
because they both provide different information on the relationship between the parent
proxy and child self reports. The parent proxy consistently rated the HRQL as worse
compared to the child report, for most of the general and neuromuscular summaries,
however not all results were significantly different. The parent proxy and child scores
were comparable for the fatigue summary, with the parent’s reporting higher HRQL than
the child for the “cognitive fatigue”, but lower for the “general fatigue” summary score.
Overall, the parents’ ratings tend to be lower than the child self-report across most
measures of HRQL. This finding has been consistently reported across a number of
different pediatric chronic conditions.(74-76) There may be a few explanations for this.
First of all, children may have adapted to their illness better than their parents because
they live with the condition daily and had to reconcile their health situation, or it may be
due to the fact that they have never known any other health status. Therefore, they may
be less likely to see the impact of their health on their quality of life as dramatically as
their parents. Additionally, parents are better able to anticipate the future than their
children, and therefore more likely to be burdened by thoughts and fears regarding their
child’s disease, which may influence their assessment of their child’s HRQL score.
Cremeens et al. 2006 suggested the poor agreement between parent and child PedsQL
scores can also be due to other factors such as the statistical methods used, the domains
of the PedsQL investigated, the age of the child, and the parents own QoL. (77)
The agreement between the child self-reported and parent proxy-reported scores ranged
from “poor” to “good”. Agreement was highest in the fatigue total score, the cognitive
fatigue score, and the emtional summary score. However, agreement was lowest in the
“social” and “physical” domains, and the “about my family resource” domains.
It is important to note that the results from the paired t-test did not always give the same
result as the ICC analysis. For example, although the PedsQL Generic physical summary
score had an ICC of 0.19 (-0.19, 0.53) showing no agreement between the parent and
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child scores, the paired t-test for the physical summary score only showed a mean
difference of 4.18 (P = 0.5). This could be due to the fact that the ICC takes the the interrater reliability of the ratings into account, whereas the paired t-test only takes mean
difference into consideration.(72) ICC may be the more appropriate test for this analysis,
given that one is comparing two raters on a construct, however much work still needs to
be done in this field to understand the best way to integrate and understand parent-proxy
in relation to child HRQL.
Previous studies have also shown a poor level of agreement between parents and children
with other chronic neuromuscular conditions.(74, 76, 78) The results from the literature
review reported five studies that assesed the correlation and agreement between the
parent proxy and child reported questionnaires. (36-38, 43, 49) However, only
Iannaccone et al. 2009 performed an ICC to test differences between the parent and child
PedsQL Generic and NM scores. The results showed that the parent-child agreement
ranged from poor to fair agreements.(49) Although, Iannccone did not report on the
fatigue module, they had similar ICC results to our general and NM modules. Their
greatest agreement is found on the Total Generic Core (0.49 ) and About my
Nueormuscular Disease (0.48) domains, which was also rated with higher agreement in
our study (Total Generic [0.53]; About my Neuromuscular Disease: [0.61]). Additionally,
their lowest overall agreement is in the ”About our family resources” (0.33) domain
which was also rated with lower agreement in our study (0.28). However, their
“emotional” (0.37) domain had a low agreement, compared to ours which had a moderate
agreement (0.67).
The original hypothesis for this objective stated that childeren’s self assessments of their
HRQL and the parent proxy assessments would be more similar for HRQLdomains
related to physical domains than emotional/social domains. Based on the paired t-tests,
the domains with the largest descrepancy in scores between the child self-report and
parent proxy-reports are the PedsQL NM total and summary scores (“about my
neuromuscular disease”, “communication”, “about our family resources”), and the
domains with the smallest descrepancies were PedQL Generic total score and the PedsQL
generic fatigue total score.
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Using the ICC analysis the domains with the lowest agreement appeared to be “About
our family resources”, “social”, and “physical summary” domains, and those with the
highest ICC were the total Fatigue score and “cognitive fatigue” summary score, along
with the “emotional” summary score. Overall, the findings from this study were
somewhat consistent with the original hypothesis. The child and parent proxy
assessments for the HRQL domains related to most of the emotional/social domains
were least similar. However, there was a not as clear a pattern of similarity on the
physical domains.
Ultimately our results would suggest that it remains difficult to determine the best way to
interpret the dynamics between parent and child ratings of child HRQL. Researchers
should still use both child self-report and parent proxy-report to get a comprehensive
understanding of HRQL, especially when measuring interventions that could have a
potential impact on HRQL in children with SMA. There is a need for additional studies to
be done in this area to determine the HRQL and subscale constructs that are most
consistent between the parent and child.

Objective 3: To explore associations between both the child reported
and parent/caregiver proxy HRQL scores to clinical and
family characteristics in children with SMA
The third obective was to explore associations between both the child reported and
parent/caregiver proxy HRQL scores and clinical and family characteristics in children (≥
5 years) with SMA. Based on the exploratory nature of this objective, a combination of a
literature review, clinical expertise, and bivariate analyses were used to determine the
variables included in the regression model. The following variables were included in the
regression model predicting the child and parent proxy-reported scores: Fatigue score,
ventilation, ambulation, and SMA type. Based on the multivaribale regression analysis
for both parent and child HRQL scores, the factor most consistently associated with
HRQL outcomes was fatigue. Fatigue was significantly associated with most of the
HRQL outcomes for both child and parent reports, where lower (less) fatigue levels were
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associated with higher (better) HRQL. In addition to fatigue, other clinical factors such as
SMA type, ventiltion and ambulation were also significantly associated with at least one
of the HRQL scores.
The strong relationship between fatigue and HRQL in children with SMA has been a
novel finding from this study. This finding is consistent with studies of other NM
conditions, specifically boys with DMD, which have also shown fatigue to be
significantly associated with HRQL.(59) The measurement of subjectve fatigue in SMA
needs to be further elucidated and understood in the SMA population. Given that our
results point to fatigue as an important factor, we recognize that understanding perceived
fatigue in terms of the clarity of the constructs, how to best measure perceived fatigue,
how to clinically improve perceived fatigue and how patients understand it are all
compelling research questions. We hope that the findings from our study will prompt
further research in this area.
There were three hypotheses for this objective. The first being children whose families
have higher socio-economic status have better HRQL, as reported by both child and
parent/caregiver, compared to children from families with lower socio-economic status.
Second, children who have a lower level of functioning have poorer HRQL, as reported
by both child and parent/caregiver. Lastly, children who are diagnosed with a more
severe type of SMA have poorer HRQL, as reported by both child and parent/caregiver,
compared to children who are diagnosed with a less severe type of SMA.
Based on the results from our regression analyses, the variables of total yearly income
and parental education were not significantly associated with any of the HRQL scores in
the bivariate analysis. This may have been due to the fact that parents in our sample have
higher educational attainment and a higher total household income compared to the
general Canadian population, thus distorting the relationship between SES and HRQL.
Secondly, the results show that children who have a lower level of functioning do in fact
have worse HRQL scores, consistent with our hypothesis. For example, those who have a
tracheostomy or use a Bi-PAP machine to assist with their ventilation have a lower
neuromuscular score compared to those who do not, for both child and parent reported
scores. Additionally, those who are ambulatory have a better physical summary score
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compared to those who are not ambulatory, in the child reported scores. Third, the results
also show that children who are diagnosed with a more severe form of SMA, tend to have
worse HRQL scores compared to those with a less severe form. For example, those with
SMA type 4 (less severe) tend to have better general, physical, and psychosocial HRQL
scores compared to those diagnosed with SMA type 2 (more severe).

5.1 Strengths and Limitations
Strengths
There are a couple key strengths of our study. First, this study provides a comprehensive
examination of HRQL in children with SMA, by capturing the HRQL from both the
children’s and parent’s perspectives with both generic and disease specific measures.
Secondly, this study is one of the first studies to use a national registry to recruit
participants and therefore creates a more representative sample than studies which
recruited participants from individual sites. Other single center studies are likely to come
from research intensive centers with a specific interest in HRQL and therefore may not
give the true picture of HRQL in the general SMA population. The value of real-world
data such as the data that is collected in the CNDR can be very important for many SMA
stakeholders for various reasons. These stakeholders include patient advocacy
organizations, clinical care guidelines and health policy makers. The data we have
described are relevant in the current environment of new therapies, as society grapples
with health economic decisions for expensive drugs for rare disease. Additionally,
although our sample was small, given that SMA is a relatively rare disease, the study was
able to capture an adequate sample size of the Canadian population with SMA. Lastly, to
our knowledge, this is the first North American study to examine the independent
association of clinical and demographic factors with child and parent reported HRQL
scores. Although other studies have performed a correlation to assess whether certain
clinical and demographic factors were associated with the HQRL scores, this is the first
study that performed a multivariable regression. A multivariable regression analysis is
important for the assessment of multiple independent variables that subsequently allows
for the assessment and adjustment for confounders that could distort the relationship
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between the dependent and individual independent variables. Therefore, although we had
a small sample size, the comprehensive process we used will be very valuable for others
working in this area to build upon.

Limitations
There were also some limitations in our study. First, the study had a small sample size
which impacted the types of analyses that were conducted, as well as the number of
covariates included in the regression mode. Any interpretation of results must be done
with caution, due to this small sample size. Secondly, although no statistical differences
were found between the clinical and demographic characteristics for responders and nonresponders, selection bias may have occurred because there could have been differences
between potential confounders that we were did not measure between the two groups.
Additionally, the responder information was taken from the returned questionnaires and
the non-responder information was taken from their clinical database. This could result in
some information bias since the questionnaire information from responders could be
more current and the registry information could potentially be more correct since it’s a
health care worker who is filling it in as opposed to the parent. Furthermore, the
respondents were taken from a clinic-based registry (CNDR) and only families who
indicated they were interested in research were mailed a questionnaire. Therefore, there
may be differences between the families who said they were interested in research
compared to families who were not interested in research. Third, this was a crosssectional study design; therefore, no causation or casual inferences can be made between
the independent variables and the HRQL outcomes. This is particularly important for the
concepts of HRQL and fatigue where they are likely interrelated constructs and
separating them will be complex. This study is part of a longitudinal study to determine
the temporal associations, which will be helpful in informing the question of causality.
Additionally, there may be bias regarding how the questions were answered. The
instructions specifically asked the parents to not guide the child when answering their
questions, however there may still be bias from the parents when the children are filling
out the forms. If the parents did influence the responses of the child, this may lead to both
the parents and child having similar answers. However, considering the large discrepancy
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and disagreement between the child and parent scores, we do not think this was an issue
in our sample. Another limitation is that the PedsQL questionnaires was only designed
for children ages 5 and up and of those children, only those who were cognitively abled
responded to the questionnaire. This could have biased the results because those who
were unable to answer the questionnaires given their age or cognitive ability, may have
had worse HRQL scores compared to those who were able to answer the questionnaires.
The final limitation is regarding the generalizability concerns because the parents in our
sample have a higher educational attainment and total household income compared to the
general Canadian population. Seventy-eight percent of the families obtained some type of
post-secondary education, and 36% of families reported an income of over ≥$150,000 a
year. This is in comparison to the median after-tax income of Canadian families of
$62,900 in 2019, and only 54.0% of Canadians aged 25 to 64 had either college or
university qualifications.(79, 80) Therefore, if the people who participated in the study
differ from the general Canadian population, this may impact the generalizability of the
study and study results.

5.2 Implications
This study examined HRQL in a sample of children with SMA in Canada using a
national registry. Due to the clinic-based registry from the CNDR, this study was able to
include a broad representative sample of patients from different clinics and regions. The
results from this study replicated prior findings that children with SMA report worse
HRQL scores, compared to healthy children from both the children’s and parent’s
perspectives. We found the social and school aspects of the HRQL are more affected
compared to the psychosocial and emotional aspect, as reported by both the children and
parents. The social aspects of the questionnaires include questions such as “getting along
with other children”, “keeping up playing with other children”, and “getting teased by
other children”. The school aspect of the questionnaires includes questions such as
“paying attention in class” and “keeping up with schoolwork”. In a study assessing the
schools and families’ perceptions of the needs of children with chronic illnesses, the
barriers identified by families included the teachers’ misunderstanding of the needs of the
child and misinformation about the illness. The most common barriers identified by the
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school district was lack of funding, and lack of public and staff awareness.(81) Given this
knowledge, more supports should be in place to improve the social and school supports
for children with SMA, where additional school services could be implemented to reduce
barriers and stigma for children with chronic illnesses.
Similar to previous studies of children with chronic conditions, this study also showed
that HRQL scores from the child and parent perspectives are usually not in agreement
with each other, with the parent usually assessing the child’s HRQL as lower than how
the child scores their own. The implications of the discrepancy between child and parent
HRQL assessments are important because it is usually the parents’ perceptions of their
child’s HRQL that are used to inform their child’s treatment decisions. Additionally,
there are circumstances where the child is too young, cognitively impaired, or too ill to
report on their own HRQL. Therefore, due to the discrepancy between parent and child
HRQL, child self-report should be taken into careful consideration, to avoid potential
negative implications of relying on the parent proxy ratings alone. At this point, given the
unclear pattern of parent proxy and child self-report HQOL we would recommend the use
of both perspectives for both generic and disease specific measures in future research and
clinical settings, to understand the breadth of outcomes when examining HRQL
This study identified perceived fatigue as a factor associated with several HRQL
outcomes. Although fatigue is commonly seen in adults with a neuromuscular condition,
it is not well studied in children with neuromuscular conditions, such as children with
SMA. The findings of our study suggest it should be taken into consideration when
caring for children with SMA. Considering perceived fatigue may be a modifiable factor,
unlike ambulation or ventilation, future research should be done on the specific aspects of
fatigue that contribute to a patients HRQL. This would allow healthcare workers to target
this area of fatigue and develop effective therapeutic strategies that may ultimately
increase the patients HRQL. There have been previous studies conducted in adults with
Rheumatoid Arthritis, Multiple Sclerosis, cancer, and other chronic conditions regarding
strategies on how to effectively reduce their perceived fatigue. Some of these
interventions include pharmacological interventions, exercise, and cognitive behavioral
therapy.(82-87) Additionally, fatigue outcome measures ought to be included as a
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secondary outcome in studies, in conjunction with HRQL questionnaires such as the
PedsQL. This would allow us to determine whether the treatment/intervention improved
the HRQL of the child, in addition to the other physical assessments and may help
determine clinically meaningful benefit.

5.3 Conclusion and Future Directions
HRQL of domains related to physical function were more affected than domains related
to fatigue and emotions, from both parent and child perspectives. The HRQL of children
with SMA as reported by the child self-report and parent-report are worse compared to
the healthy children in all domains, and worse in the physical domains compared to
children with other chronic conditions such as DMD. The parent proxy consistently
reported worse HRQL compared to the child report for most of the general and NM
modules, however not all differences were statistically significant. Agreement between
parents and their children with SMA on children’s level of HRQL ranged from good to
poor. Lastly, greater fatigue appeared to be associated with lower HRQL in most domains
and warrants further attention from researchers and healthcare-workers.
This study is part of a 3-year longitudinal study. With a longitudinal study, we can start to
establish a temporal relationship between the independent variables and the HRQL
outcomes. Additionally, due to the recent medical and treatment advancements for
children with SMA, there has been a large increase in the number of CNDR participants
indicating they are interested in research. This may increase the sample size of the
longitudinal study, allowing us to be more confident in our conclusions regarding the
aspects of HRQL. This will be critical for the development of future research studies and
most importantly, for the clinical care of children living with SMA.
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Table 5-1 Mean Self-Reported PedsQL core in Children with SMA: Comparison to the
Iannaccone et al 2009 Study
N

Study results

N

Study results from
Iannaccone et al
2009

Generic Core
Total Score

32

57.35 (13.83)

125

58.7 (14.4)

Physical
summary

32

31.63 (18.47)

123

43.4 (21.2)

Psychosocial
summary

33

70.41 (15.66)

125

66.6 (16.3)

Emotional

33

74.85 (18.31)

125

67.0 (23.0)

Social

33

66.52 (17.57)

125

66.1 (19.5)

School

33

68.33 (18.10)

124

66.2 (20.9)

Neuromuscular
Module Total
Score
About my
neuromuscular
disease
Communication

33

65.77 (16.04)

123

67.5 (15.6)

33

63.38 (17.91)

123

65.9 (16.5)

28

72.32 (24.43)

80

70.8 (23.6)

About our
family resources

28

73.57 (20.68)

80

74.7 (22.2)

Comparison to
Iannaccone et al 2009
Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
-1.35 (-6.90, 4.20)
[2.83]
P = 0.63
-11.67 (-19.71, -3.63)
[4.10]
P = 0.01
3.810 (-2.39, 10.01)
[3.17]
P = 0.23
7.85 (-0.64, 16.34)
[4.33]
P = 0.07
0.42 (-6.91, 7.75)
[3.74]
P = 0.91
2.13 (-5.68, 9.94)
[3.99]
P = 0.59
-1.73 (-7.76, 4.30)
[3.08]
P = 0.58
-2.52 (-8.98, 3.94)
[3.29]
P = 0.45
1.52 (-8.73, 11.77)
[5.23]
P = 0.77
-1.13 (-10.52, 8.26)
[4.79]
P = 0.81
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Table 5-2 Mean Parent Reported PedsQL Score in Children with SMA:
Comparison to the Iannaccone et al 2009 Study
N

Study results

N

Study results from
Iannaccone et al
2009

Generic Core
Total Score

42

54.48 (13.85)

174

53.4 (14.2)

Physical
summary

39

34.48 (26.50)

172

36.3 (24.6)

Psychosocial
summary

42

64.67 (13.03)

174

74.8 (18.2)

Emotional

43

71.16 (18.09)

173

62.2 (17.6)

Social

42

57.98 (17.43)

174

57.4 (17.4)

School

39

61.41 (19.70)

154

63.8 (20.0)

Neuromuscular
Module Total
Score
About my
neuromuscular
disease
Communication

43

54.19 (17.70)

172

59.7 (16.8)

43

54.51 (19.76)

176

58.8 (17.7)

43

61.05 (27.68)

172

67.0 (31.1)

About our
family resources

43

48.95 (22.77)

176

59.6 (22.2)

Comparison to Iannaccone
et al 2009
Mean Difference (MD)
95% CI
Standard Error (SE)
P-Value
1.08 (-3.68, 5.84)
[2.43]
P = 0.66
-1.82 (-10.50, 6.86)
[4.43]
P = 0.68

-10.13 (-14.91, -5.35)
[2.44]
P < 0.001
8.96 (3.05, 14.87)
[3.02]
P = 0.003
0.58(-5.29, 6.45)
[2.99]
P = 0.85
-2.39 (-9.40, 4.62)
[3.58]
P = 0.51
-5.51 (-11.19, 0.17)
[2.90]
P = 0.06
-4.29 (-10.33, 1.75)
[3.08]
P = 0.17
-5.95 (-16.13, 4.23)
[5.19]
P = 0.25
-10.65 (-18.09, -3.21)
[3.80]
P = 0.005
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Appendices
Appendix A. Search Strategy
EMBASE
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

Spinal muscular atrophy.mp.
SMA.mp.
1 or 2
Healthy related quality of life.mp.
health-related quality of life.mp.
HRQL.mp.
HRQOL.mp.
Quality of life.mp.
QOL.mp.
4 or 5 or 6 or 7 or 8 or 9
Pediatric.mp.
Paediatric.mp.
Child*.mp.
11 or 12 or 13
3 and 10 and 14

MEDLINE
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

Spinal muscular atrophy.mp.
SMA.mp.
1 or 2
Healthy related quality of life.mp.
health-related quality of life.mp.
HRQL.mp.
HRQOL.mp.
Quality of life.mp.
QOL.mp.
4 or 5 or 6 or 7 or 8 or 9
Pediatric.mp.
Paediatric.mp.
Child*.mp.
11 or 12 or 13
3 and 10 and 14
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Cochrane
#1 MESH descriptor: [Muscular Atrophy] explode all trees
#2 SMA
#3 #1 or #2
#4 MESH descriptor: [Quality of Life] explode all trees
#5 Healthy related quality of life
#6 health-related quality of life
#7 HRQL
#8 HRQOL
#9 Quality of life
#10 QoL
#11 #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 Pediatric
#13 Paediatric
#14 Child*
#15 #12 or #13 or #14
#14 #3 and #11 and #15
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